https://trial.medpath.com/news/strong-safety-nuanced-efficacy-results-for-canakinumab-in-previously-treated-mds 2024-12-05T18:29:59+00:00 weekly 0.7 https://trial.medpath.com/news/long-term-efficacy-of-first-line-afatinib-and-the-clinical-utility-of-ctdna-monitoring-in-patients 2024-12-05T18:28:37+00:00 weekly 0.7 https://trial.medpath.com/news/lundbeck-highlights-commitment-to-the-rare-epilepsy-community-at-american-cision-news 2024-12-05T18:08:47+00:00 weekly 0.7 https://trial.medpath.com/news/rubi-secures-1-million-phase-ii-grant-from-the-national-science-foundation-to-scale-its 2024-12-05T17:50:39+00:00 weekly 0.7 https://trial.medpath.com/news/evaluation-of-a-mobile-application-to-decrease-opioid-misuse-in-patients-undergoing 2024-12-05T17:31:51+00:00 weekly 0.7 https://trial.medpath.com/news/the-long-journey-of-a-small-molecule-of-hope-research-horizons 2024-12-05T17:26:09+00:00 weekly 0.7 https://trial.medpath.com/news/study-finds-tonsil-removal-not-linked-to-weight-gain-contrary-to-popular-belief-michigan-medicine 2024-12-05T16:05:12+00:00 weekly 0.7 https://trial.medpath.com/news/december-5-2024-nudge-pragmatic-trial-finds-no-improvement-in-adherence-to 2024-12-05T15:44:52+00:00 weekly 0.7 https://trial.medpath.com/news/simcha-therapeutics-announces-the-opening-of-two-clinical-studies-exploring-st-067-in 2024-12-05T15:31:45+00:00 weekly 0.7 https://trial.medpath.com/news/unlearn-and-apst-research-partner-to-build-high-quality-dataset-to-accelerate-als-clinical-trials 2024-12-05T15:16:28+00:00 weekly 0.7 https://trial.medpath.com/news/suo-2024-in-depth-characterization-of-the-safety-profile-of-belzutifan-monotherapy-in-urotoday 2024-12-05T15:15:16+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-eligibility-and-outcomes-in-patients-with-metastatic-nsclc-treated-outside-of 2024-12-05T15:05:10+00:00 weekly 0.7 https://trial.medpath.com/news/ryvu-therapeutics-announces-dosing-of-the-first-patient-in-the-potami-61-phase-ii-study 2024-12-05T14:53:26+00:00 weekly 0.7 https://trial.medpath.com/news/protara-therapeutics-inc-announces-positive-results-from-the-ongoing-phase-2-advanced 2024-12-05T14:49:25+00:00 weekly 0.7 https://trial.medpath.com/news/her2-gastric-cancer-market-report-2032-epidemiology-openpr-com 2024-12-05T14:47:38+00:00 weekly 0.7 https://trial.medpath.com/news/mission-bio-showcases-critical-insights-into-multiple-myeloma-aml-mrd-car-t-safety 2024-12-05T14:39:22+00:00 weekly 0.7 https://trial.medpath.com/news/simx-receives-1-25m-phase-ii-sttr-grant-from-afwerx-to-advance-vr-training-for 2024-12-05T13:52:57+00:00 weekly 0.7 https://trial.medpath.com/news/cu-cancer-center-member-breelyn-wilky-md-oversees-trial-of-new-treatment-for-sarcomas 2024-12-05T13:36:45+00:00 weekly 0.7 https://trial.medpath.com/news/aurobindo-pharma-wins-usfda-approval-for-generic-cancer-drug-the-hindu-businessline 2024-12-05T13:09:46+00:00 weekly 0.7 https://trial.medpath.com/news/suo-2024-disease-free-survival-and-overall-survival-in-patients-with-high-risk-muscle 2024-12-05T13:09:17+00:00 weekly 0.7 https://trial.medpath.com/news/annexon-to-present-phase-2-archer-data-on-protection-of-globenewswire 2024-12-05T13:02:51+00:00 weekly 0.7 https://trial.medpath.com/news/theriva-biologics-gets-fda-guidance-on-vcn-01-phase-3-trial-design-for-pancreatic 2024-12-05T13:02:05+00:00 weekly 0.7 https://trial.medpath.com/news/denali-therapeutics-launches-key-phase-2a-trial-for-breakthrough-parkinson-s-treatment 2024-12-05T13:02:03+00:00 weekly 0.7 https://trial.medpath.com/news/imfinzi-approved-in-the-us-as-first-and-only-immunotherapy-regimen-for-patients-with-limited 2024-12-05T13:01:23+00:00 weekly 0.7 https://trial.medpath.com/news/single-versus-tandem-autologous-stem-cell-transplantation-in-newly-diagnosed-multiple-myeloma 2024-12-05T12:41:36+00:00 weekly 0.7 https://trial.medpath.com/news/theralase-r-launches-new-clinical-study-site-in-canada-corsicana-daily-sun 2024-12-05T12:22:53+00:00 weekly 0.7 https://trial.medpath.com/news/yap1-and-kras-identified-as-key-drivers-in-soft-tissue-sarcoma-development-opening-new-treatment-avenues 2024-12-05T12:19:35+00:00 weekly 0.7 https://trial.medpath.com/news/the-us-fda-approves-ibox-french-algorithm-for-predicting-kidney-graft-survival 2024-12-05T12:11:47+00:00 weekly 0.7 https://trial.medpath.com/news/ntc-presents-positive-results-from-phase-ii-mirakle-study-evaluating-an-innovative-drug-for 2024-12-05T11:56:19+00:00 weekly 0.7 https://trial.medpath.com/news/merck-and-ridgeback-biotherapeutics-announce-initiation-of-phase-3-study-move-now 2024-12-05T11:50:10+00:00 weekly 0.7 https://trial.medpath.com/news/kalvista-pharmaceuticals-reports-second-fiscal-quarter-results-and-provides-operational-update 2024-12-05T11:35:35+00:00 weekly 0.7 https://trial.medpath.com/news/most-young-people-with-long-covid-recover-within-2-years 2024-12-05T11:12:20+00:00 weekly 0.7 https://trial.medpath.com/news/nanox-secures-major-fda-clearance-expansion-for-revolutionary-digital-x-ray-system 2024-12-05T11:03:36+00:00 weekly 0.7 https://trial.medpath.com/news/media-advisory-abnormal-prenatal-blood-test-results-could-indicate-hidden-maternal-cancers 2024-12-05T10:04:13+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-outsourcing-market-set-to-reach-91-2-billion-by-2034-driven-by-technology-integration-and-strategic-partnerships 2024-12-05T09:31:39+00:00 weekly 0.7 https://trial.medpath.com/news/safety-and-effectiveness-of-transcutaneous-auricular-vagus-nerve-stimulation-on-patients 2024-12-05T09:26:52+00:00 weekly 0.7 https://trial.medpath.com/news/uk-first-country-in-europe-to-reimburse-tirzepatide-european-biotechnology-magazine 2024-12-05T09:21:52+00:00 weekly 0.7 https://trial.medpath.com/news/who-senior-adviser-calls-for-systematic-reviews-to-address-clinical-trial-diversity-gap 2024-12-05T08:59:25+00:00 weekly 0.7 https://trial.medpath.com/news/avistone-announces-updates-on-ans03-biospace 2024-12-05T08:25:09+00:00 weekly 0.7 https://trial.medpath.com/news/3-asx-biotech-shares-rocketing-10-to-26-on-big-news-motley-fool 2024-12-05T08:09:30+00:00 weekly 0.7 https://trial.medpath.com/news/first-cd20xcd3-antibody-shows-survival-benefits-in-phase-iii-lymphoma-trial-rhhby-stock-news 2024-12-05T08:05:42+00:00 weekly 0.7 https://trial.medpath.com/news/theralase-technologies-inc-tltff-q3-2024-earnings-call-highlig-gurufocus 2024-12-05T07:28:34+00:00 weekly 0.7 https://trial.medpath.com/news/physiomics-secures-new-contract-with-numab-therapeutics-for-inflammation-study 2024-12-05T07:14:01+00:00 weekly 0.7 https://trial.medpath.com/news/ips-test-shows-promise-in-guiding-immunotherapy-decisions-for-solid-tumor-treatment 2024-12-05T07:01:43+00:00 weekly 0.7 https://trial.medpath.com/news/cyp-006tk-demonstrates-safety-and-efficacy-in-dfu-clinical-trial-biospace 2024-12-05T06:48:02+00:00 weekly 0.7 https://trial.medpath.com/news/acrux-gains-fda-approval-and-raises-2-65-million-markets-insider 2024-12-05T06:46:01+00:00 weekly 0.7 https://trial.medpath.com/news/nxera-pharma-enrolls-first-insomnia-patient-in-its-phase-3-globenewswire 2024-12-05T06:07:20+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-advances-in-lung-cancer-treatment-combine-early-detection-and-personalized-therapies 2024-12-05T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/gut-microbiota-modulation-a-novel-mechanism-in-arb-mediated-hypertension-treatment 2024-12-05T05:56:08+00:00 weekly 0.7 https://trial.medpath.com/news/anatara-provides-irritable-bowel-syndrome-clinical-trial-update-biotech-dispatch 2024-12-05T05:23:09+00:00 weekly 0.7 https://trial.medpath.com/news/how-bad-is-fraud-in-alzheimer-s-research-q-a-with-neurologist-sleuth-matthew-schrag 2024-12-05T05:17:26+00:00 weekly 0.7 https://trial.medpath.com/news/durvalumab-wins-fda-approval-in-limited-stage-small-cell-lung-cancer 2024-12-05T04:59:33+00:00 weekly 0.7 https://trial.medpath.com/news/edgewise-therapeutics-swot-analysis-biotech-stock-poised-for-growth-amid-clinical-milestones 2024-12-05T04:44:11+00:00 weekly 0.7 https://trial.medpath.com/news/us-abortion-laws-could-deter-women-s-participation-in-clinical-research-raising-scientific-and-ethical-concerns 2024-12-05T04:38:17+00:00 weekly 0.7 https://trial.medpath.com/news/how-cedars-sinai-increased-black-and-hispanic-clinical-trial-enrollment-blackdoctor-org 2024-12-05T04:10:59+00:00 weekly 0.7 https://trial.medpath.com/news/terns-pharmaceuticals-allosteric-inhibitor-shows-best-in-class-potential-in-phase-i-cml-study 2024-12-05T04:07:05+00:00 weekly 0.7 https://trial.medpath.com/news/tirzepatide-shows-47-greater-weight-loss-than-semaglutide-in-72-week-phase-3b-study 2024-12-05T03:54:55+00:00 weekly 0.7 https://trial.medpath.com/news/appeals-court-denies-novartis-bid-to-block-generic-entresto-threatening-5-6b-revenue-stream 2024-12-05T03:14:20+00:00 weekly 0.7 https://trial.medpath.com/news/matica-biotechnology-partners-with-treovir-on-hsv-vectors-for-pediatric-brain-tumor-therapy 2024-12-05T01:35:33+00:00 weekly 0.7 https://trial.medpath.com/news/pancreatic-cancer-patient-survival-doubled-with-high-dose-of-common-vitamin-study-finds 2024-12-05T00:51:13+00:00 weekly 0.7 https://trial.medpath.com/news/suo-2024-real-world-treatment-and-clinical-outcomes-in-patients-with-mcrpc-treated 2024-12-05T00:29:28+00:00 weekly 0.7 https://trial.medpath.com/news/singapore-leads-asia-in-groundbreaking-gene-editing-trial-for-rare-heart-disease 2024-12-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/high-tumor-mutational-burden-linked-to-improved-survival-in-metastatic-colon-cancer 2024-12-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/singapore-launches-25-million-clarion-program-to-transform-asian-lung-cancer-treatment 2024-12-05T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/lenvatinib-pembrolizumab-vs-chemotherapy-in-advanced-endometrial-cancer 2024-12-04T23:45:10+00:00 weekly 0.7 https://trial.medpath.com/news/can-fite-announces-8-year-survival-for-patient-in-phase-2-liver-cancer-study 2024-12-04T23:41:05+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-rare-pediatric-disease-to-101-pgc-005-for-systemic-juvenile-idiopathic-arthritis 2024-12-04T23:37:29+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-revascor-r-rexlemestrocel-l-regenerative-globenewswire 2024-12-04T23:36:34+00:00 weekly 0.7 https://trial.medpath.com/news/race-oncology-advances-rc220-phase-1-cancer-trial-tipranks-com 2024-12-04T22:57:00+00:00 weekly 0.7 https://trial.medpath.com/news/editorial-hong-kong-drug-trials-institute-a-healthy-step-forward 2024-12-04T22:18:12+00:00 weekly 0.7 https://trial.medpath.com/news/novel-heart-stent-for-kids-draws-praise-research-horizons 2024-12-04T22:17:30+00:00 weekly 0.7 https://trial.medpath.com/news/breaking-new-ground-in-immunology-inflammation-inside-precision-medicine 2024-12-04T22:17:21+00:00 weekly 0.7 https://trial.medpath.com/news/suo-2024-mevrometostat-pf-06821497-in-combination-with-enzalutamide-in-patients 2024-12-04T22:04:04+00:00 weekly 0.7 https://trial.medpath.com/news/biotech-startup-avoids-sec-penalties-through-voluntary-self-report-legal-dive 2024-12-04T22:03:54+00:00 weekly 0.7 https://trial.medpath.com/news/corvus-pharma-s-cancer-drug-shows-breakthrough-immune-response-in-nature-journal-study 2024-12-04T21:14:24+00:00 weekly 0.7 https://trial.medpath.com/news/penn-state-college-of-medicine-beat-childhood-cancer-research-consortium-leading 2024-12-04T20:20:09+00:00 weekly 0.7 https://trial.medpath.com/news/eyepoint-doses-first-patient-in-second-global-phase-3-lucia-clinical-trial-of-duravyu-for-the 2024-12-04T20:09:01+00:00 weekly 0.7 https://trial.medpath.com/news/fda-finalizes-pccp-guidance-for-ai-enabled-medical-devices-akin-gump 2024-12-04T19:13:18+00:00 weekly 0.7 https://trial.medpath.com/news/ngs-and-novel-therapies-lends-to-prolonged-survival-outcomes-in-hr-her2-breast-cancer 2024-12-04T19:11:14+00:00 weekly 0.7 https://trial.medpath.com/news/what-to-know-about-metastatic-prostate-cancer 2024-12-04T19:02:27+00:00 weekly 0.7 https://trial.medpath.com/news/all-leukemia-clinical-studies-ongoing-recruitment-and-more-medicalnewstoday 2024-12-04T18:45:28+00:00 weekly 0.7 https://trial.medpath.com/news/phanes-therapeutics-pt217-granted-fast-track-designation-by-the-fda-for-nepc 2024-12-04T18:42:07+00:00 weekly 0.7 https://trial.medpath.com/news/impact-of-prior-dengue-infection-on-severity-and-outcomes-meta-analysis-of-placebo-controlled-trials 2024-12-04T18:42:06+00:00 weekly 0.7 https://trial.medpath.com/news/restem-receives-fda-orphan-drug-designation-for-its-ulsc-program-for-the-treatment-of 2024-12-04T18:39:32+00:00 weekly 0.7 https://trial.medpath.com/news/sinai-health-s-innovative-clinical-trial-framework-leads-to-transformative-advances-in 2024-12-04T18:16:21+00:00 weekly 0.7 https://trial.medpath.com/news/ultrasound-controlled-crispr-offers-precision-in-treating-genetic-disorders-news-medical 2024-12-04T18:15:15+00:00 weekly 0.7 https://trial.medpath.com/news/initial-safety-findings-reported-on-luspatercept-plus-lenalidomide-for-non-del-5q-mds 2024-12-04T18:11:58+00:00 weekly 0.7 https://trial.medpath.com/news/dewpoint-mitsubishi-partner-on-als-drug-in-deal-worth-up-to-480m-biopharma-dive 2024-12-04T18:11:11+00:00 weekly 0.7 https://trial.medpath.com/news/phase-ii-iii-pooled-data-analysis-imetelstat-benefit-in-mds-independent-of-prior-therapy 2024-12-04T17:51:09+00:00 weekly 0.7 https://trial.medpath.com/news/toripalimab-plus-chemotherapy-in-first-line-therapy-for-extensive-stage-small-cell-lung-cancer 2024-12-04T17:50:37+00:00 weekly 0.7 https://trial.medpath.com/news/md-anderson-research-highlights-ash-2024-special-edition 2024-12-04T17:39:35+00:00 weekly 0.7 https://trial.medpath.com/news/health-net-grant-for-uc-davis-stem-cell-program-to-improve-access-to-car-t-cell-therapy 2024-12-04T17:34:43+00:00 weekly 0.7 https://trial.medpath.com/news/review-highlights-gaps-in-publicly-funded-non-inferiority-clinical-trials-call-for-better 2024-12-04T17:17:22+00:00 weekly 0.7 https://trial.medpath.com/news/cidara-s-phase-ii-trial-testing-cd388-for-flu-prevention-fully-enrolled-with-5000-subjects 2024-12-04T16:51:57+00:00 weekly 0.7 https://trial.medpath.com/news/early-detection-and-interception-research-shows-promise-at-ash 2024-12-04T16:44:20+00:00 weekly 0.7 https://trial.medpath.com/news/antag-therapeutics-secures-eur80-million-in-weight-loss-therapy-financing-pharmatimes 2024-12-04T16:12:38+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-data-and-patient-planning-can-keep-trials-from-collapsing-clinical-trials-arena 2024-12-04T16:11:38+00:00 weekly 0.7 https://trial.medpath.com/news/l-arginine-shows-potential-in-treating-spinocerebellar-ataxia-type-6-news-medical 2024-12-04T16:03:16+00:00 weekly 0.7 https://trial.medpath.com/news/stent-omission-after-ureteroscopy-and-lithotripsy-soul-in-the-michigan-urological-trials 2024-12-04T15:33:41+00:00 weekly 0.7 https://trial.medpath.com/news/texas-cardiac-arrhythmia-institute-at-st-david-s-medical-center-first-in-u-s-to-use-fda 2024-12-04T15:26:59+00:00 weekly 0.7 https://trial.medpath.com/news/ocrelizumab-in-early-stage-relapsing-remitting-multiple-sclerosis-the-phase-iiib-pubmed 2024-12-04T14:53:16+00:00 weekly 0.7 https://trial.medpath.com/news/tribe-clinical-research-launches-new-drug-trial-focused-on-alzheimer-s-prevention 2024-12-04T14:47:12+00:00 weekly 0.7 https://trial.medpath.com/news/sonnet-biotherapeutics-unveils-breakthrough-cancer-drug-delivery-system-in-major-publication 2024-12-04T14:27:04+00:00 weekly 0.7 https://trial.medpath.com/news/vivavision-to-advance-non-steroidal-therapy-in-phase-iii-following-phase-ii-win 2024-12-04T14:16:00+00:00 weekly 0.7 https://trial.medpath.com/news/arrowhead-seeks-approval-to-begin-rnai-therapy-trial-for-obesity-treatment 2024-12-04T14:16:00+00:00 weekly 0.7 https://trial.medpath.com/news/omniscience-inc-and-inmune-bio-inc-partner-to-accelerate-a-phase-2-alzheimer-s-trial 2024-12-04T14:15:11+00:00 weekly 0.7 https://trial.medpath.com/news/idiopathic-pulmonary-fibrosis-promising-drugs-foxo3-and-beyond-labiotech 2024-12-04T14:13:04+00:00 weekly 0.7 https://trial.medpath.com/news/daratumumab-quadruplet-improves-outcomes-in-transplant-ineligible-myeloma 2024-12-04T14:11:05+00:00 weekly 0.7 https://trial.medpath.com/news/study-shows-comparable-safety-efficacy-of-idecabtagene-vicleucel-in-older-patients 2024-12-04T14:07:34+00:00 weekly 0.7 https://trial.medpath.com/news/tcbp-provides-quarterly-update-on-the-achieve-uk-clinical-trial-pr-newswire 2024-12-04T13:31:02+00:00 weekly 0.7 https://trial.medpath.com/news/adaptive-research-welcomes-western-radiation-oncology-to-globenewswire 2024-12-04T13:25:03+00:00 weekly 0.7 https://trial.medpath.com/news/outlook-therapeutics-r-announces-nice-recommendation-of-lytenavatm-bevacizumab 2024-12-04T13:25:03+00:00 weekly 0.7 https://trial.medpath.com/news/ensysce-biosciences-announces-strategic-partnership-for-the-development-and-yahoo-finance 2024-12-04T13:22:41+00:00 weekly 0.7 https://trial.medpath.com/news/windtree-announces-partnership-with-new-growth-advisors-to-leverage-positive-phase-2 2024-12-04T13:18:26+00:00 weekly 0.7 https://trial.medpath.com/news/zepbound-bests-wegovy-for-weight-loss-in-new-trial 2024-12-04T13:12:48+00:00 weekly 0.7 https://trial.medpath.com/news/egetis-has-decided-to-explore-rth-beta-as-the-next-indication-for-tiratricol-emcitate-r 2024-12-04T13:02:12+00:00 weekly 0.7 https://trial.medpath.com/news/treovir-announces-opening-of-g207-phase-2-clinical-trial-in-children-with-recurrent-brain-tumors 2024-12-04T12:48:14+00:00 weekly 0.7 https://trial.medpath.com/news/allay-therapeutics-receives-fda-breakthrough-therapy-designation-btd-for-atx101-for 2024-12-04T12:42:34+00:00 weekly 0.7 https://trial.medpath.com/news/amylyx-pharmaceuticals-announces-pivotal-phase-3-lucidity-trial-design-for-yahoo-finance 2024-12-04T12:37:56+00:00 weekly 0.7 https://trial.medpath.com/news/relmada-therapeutics-reports-that-data-monitoring-committee-globenewswire 2024-12-04T12:33:57+00:00 weekly 0.7 https://trial.medpath.com/news/atea-reports-high-efficacy-in-phase-2-hcv-treatment-study-investing-com 2024-12-04T12:24:40+00:00 weekly 0.7 https://trial.medpath.com/news/the-multiple-myeloma-research-foundation-mmrf-announces-the-first-patient-enrolled 2024-12-04T12:23:46+00:00 weekly 0.7 https://trial.medpath.com/news/teva-s-phase-3-study-of-ajovy-shows-superior-efficacy-in-migraine-prevention-for-children 2024-12-04T12:17:37+00:00 weekly 0.7 https://trial.medpath.com/news/all-three-projects-powered-by-quera-computing-contributions-move-to-phase-two-of 2024-12-04T12:15:14+00:00 weekly 0.7 https://trial.medpath.com/news/stoke-therapeutics-secures-fda-breakthrough-status-for-revolutionary-dravet-syndrome-treatment 2024-12-04T12:10:41+00:00 weekly 0.7 https://trial.medpath.com/news/tiziana-life-sciences-expands-breakthrough-ms-drug-trial-to-elite-u-s-medical-centers 2024-12-04T12:10:36+00:00 weekly 0.7 https://trial.medpath.com/news/first-single-dose-medicine-for-p-vivax-malaria-prequalified-by-who-and-included-in-who-guidelines 2024-12-04T12:10:34+00:00 weekly 0.7 https://trial.medpath.com/news/study-published-in-the-new-england-journal-of-medicine-ai-concludes-that-the-sepsis 2024-12-04T12:08:40+00:00 weekly 0.7 https://trial.medpath.com/news/astro-survey-reveals-devastating-impact-of-prior-authorization-delays-on-cancer-care 2024-12-04T11:17:28+00:00 weekly 0.7 https://trial.medpath.com/news/genes-highlight-who-ll-benefit-from-multiple-myeloma-therapy 2024-12-04T11:12:35+00:00 weekly 0.7 https://trial.medpath.com/news/high-dose-vitamin-d-supplements-won-t-prevent-diabetes-in-healthy-seniors 2024-12-04T11:12:04+00:00 weekly 0.7 https://trial.medpath.com/news/stroke-combatting-drug-developed-by-nanjing-firms-obtains-fda-approval-the-nanjinger 2024-12-04T11:10:06+00:00 weekly 0.7 https://trial.medpath.com/news/mohamad-baker-berjaoui-md-on-water-and-water-ii-findings-in-bph-urology-times 2024-12-04T11:04:34+00:00 weekly 0.7 https://trial.medpath.com/news/a-decade-of-incremental-advances-in-radiopharmaceuticals-a-promising-future-ahead 2024-12-04T10:46:46+00:00 weekly 0.7 https://trial.medpath.com/news/gate-neurosciences-and-pitt-commence-antidepressant-drug-trial-clinical-trials-arena 2024-12-04T09:46:16+00:00 weekly 0.7 https://trial.medpath.com/news/prospective-study-of-patient-nursing-and-oncology-provider-perspectives-on-telemedicine 2024-12-04T08:41:09+00:00 weekly 0.7 https://trial.medpath.com/news/leo-pharma-s-growth-hope-receives-approval-in-the-uk-medwatch 2024-12-04T08:31:56+00:00 weekly 0.7 https://trial.medpath.com/news/metabolic-and-endocrine-therapies-could-star-among-us-fda-s-last-2024-approvals 2024-12-04T07:55:11+00:00 weekly 0.7 https://trial.medpath.com/news/cytokinetics-announces-start-of-comet-hf-a-confirmatory-phase-3-clinical-trial-of-biospace 2024-12-04T07:31:03+00:00 weekly 0.7 https://trial.medpath.com/news/beyond-cancer-ltd-announces-phase-1b-clinical-trial-approval-for-lv-uno-in-barchart-com 2024-12-04T07:27:43+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-rezolute-s-ersodetug-rz358-for-the-biospace 2024-12-04T07:25:00+00:00 weekly 0.7 https://trial.medpath.com/news/a-new-hope-for-atrial-fibrillation-patients-with-breakthrough-catheter-technology 2024-12-04T07:20:59+00:00 weekly 0.7 https://trial.medpath.com/news/lupus-nephritis-clinical-trial-pipeline-experiences-momentum-delveinsight-estimates-a 2024-12-04T07:05:14+00:00 weekly 0.7 https://trial.medpath.com/news/medical-breakthrough-as-therapy-unveiled-for-untreatable-debilitating-illness-express-co-uk 2024-12-04T06:02:02+00:00 weekly 0.7 https://trial.medpath.com/news/nmpa-grants-conditional-approval-to-fruquintinib-plus-sintilimab-for-pmmr-endometrial-cancer 2024-12-04T05:26:19+00:00 weekly 0.7 https://trial.medpath.com/news/can-the-girl-power-of-arrivo-s-depression-drug-help-reverse-its-fortunes-pharmavoice 2024-12-04T05:25:12+00:00 weekly 0.7 https://trial.medpath.com/news/alterity-completes-phase-2-trial-in-multiple-system-atrophy-finance-news-network 2024-12-04T05:14:58+00:00 weekly 0.7 https://trial.medpath.com/news/protein-conformation-may-have-a-hand-in-herpes-drug-resistance-drug-discovery-news 2024-12-04T05:05:55+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-of-aptamer-based-liver-cancer-drug-to-begin-at-4-korean-hospitals-kbr 2024-12-04T04:52:54+00:00 weekly 0.7 https://trial.medpath.com/news/power-metals-test-work-produces-high-grade-cesium-concentrate-of-19-97 2024-12-04T03:48:45+00:00 weekly 0.7 https://trial.medpath.com/news/innocare-urologics-wins-fda-nod-for-urinary-safety-catheter-massdevice 2024-12-04T03:37:19+00:00 weekly 0.7 https://trial.medpath.com/news/dr-kalinsky-on-the-postmonarch-study-in-hr-her2-advanced-breast-cancer-onclive 2024-12-04T03:11:19+00:00 weekly 0.7 https://trial.medpath.com/news/pd-1-inhibitors-make-impact-in-merkel-cell-carcinoma-but-unmet-needs-persist-onclive 2024-12-04T02:57:45+00:00 weekly 0.7 https://trial.medpath.com/news/empowering-patients-exploring-self-administration-of-rozanolixizumab-for-myasthenia-gravis 2024-12-04T02:11:00+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-expert-warns-against-poor-record-keeping-risks-at-oncology-conference 2024-12-04T02:00:34+00:00 weekly 0.7 https://trial.medpath.com/news/fda-s-december-calendar-features-nine-pdufa-dates 2024-12-04T01:51:35+00:00 weekly 0.7 https://trial.medpath.com/news/mysterious-disease-outbreak-claims-143-lives-in-southwest-congo 2024-12-04T01:21:32+00:00 weekly 0.7 https://trial.medpath.com/news/icon-launches-comprehensive-patient-centric-outcome-measures-solution-for-clinical-trials 2024-12-04T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/disitamab-vedotin-shows-early-efficacy-in-her2-expressing-breast-cancer-with-pam 2024-12-04T00:55:29+00:00 weekly 0.7 https://trial.medpath.com/news/first-of-its-kind-gene-editing-treatment-saves-baby-with-rare-genetic-disorder 2024-12-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-initiates-first-in-human-phase-i-trial-for-novel-investigational-drug-d9440c00001 2024-12-04T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sudo-biosciences-begins-trial-of-drug-candidate-for-neuroinflammatory-conditions 2024-12-03T23:31:53+00:00 weekly 0.7 https://trial.medpath.com/news/theratechnologies-announces-resumed-production-of-egrifta-sv-stock-titan 2024-12-03T21:50:33+00:00 weekly 0.7 https://trial.medpath.com/news/why-does-the-approval-of-the-vaccine-take-longer-in-the-eu-telegraph-telegrafi 2024-12-03T21:46:14+00:00 weekly 0.7 https://trial.medpath.com/news/outlook-therapeutics-r-announces-executive-leadership-transition-quantisnow 2024-12-03T21:45:07+00:00 weekly 0.7 https://trial.medpath.com/news/trevi-therapeutics-nalbuphine-shows-breakthrough-abuse-resistance-in-key-clinical-study 2024-12-03T21:25:27+00:00 weekly 0.7 https://trial.medpath.com/news/uc-san-diego-and-scripps-research-join-national-team-to-make-vision-restoring-whole 2024-12-03T20:56:18+00:00 weekly 0.7 https://trial.medpath.com/news/systematic-review-shows-favorable-functional-histological-findings-for-givinostat-in 2024-12-03T20:17:39+00:00 weekly 0.7 https://trial.medpath.com/news/suo-2024-emerging-perioperative-systemic-therapy-urotoday 2024-12-03T20:05:47+00:00 weekly 0.7 https://trial.medpath.com/news/medipost-inc-expands-u-s-presence-with-key-executive-appointments-advances-biospace 2024-12-03T19:43:14+00:00 weekly 0.7 https://trial.medpath.com/news/markedly-fewer-cf-lung-transplants-since-trikafta-approval-study 2024-12-03T19:29:11+00:00 weekly 0.7 https://trial.medpath.com/news/oncolytics-biotech-r-reports-completion-of-initial-safety-phase-enrollment-for-goblet-biospace 2024-12-03T19:05:38+00:00 weekly 0.7 https://trial.medpath.com/news/maze-therapeutics-115-million-series-d-raised-to-develop-precision-medicine 2024-12-03T19:04:01+00:00 weekly 0.7 https://trial.medpath.com/news/vir-has-positive-readthrough-from-janux-data-says-morgan-stanley-markets-insider 2024-12-03T18:44:37+00:00 weekly 0.7 https://trial.medpath.com/news/irlab-s-patient-recruitment-for-pirepemat-study-slower-than-expected-marketscreener 2024-12-03T18:43:24+00:00 weekly 0.7 https://trial.medpath.com/news/three-professors-become-overnight-millionaires-after-a-major-breakthrough-in-medicine-for 2024-12-03T18:32:49+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-renal-care-enrolled-first-patients-in-the-voice-collaborative-clinical-trial-of-vafseo 2024-12-03T18:02:38+00:00 weekly 0.7 https://trial.medpath.com/news/augustana-college-offering-fda-approved-tinnitus-treatment-device-river-cities-reader 2024-12-03T17:53:44+00:00 weekly 0.7 https://trial.medpath.com/news/hansoh-pharmaceutical-group-company-limited-regulator-grants-breakthrough-therapy 2024-12-03T17:33:28+00:00 weekly 0.7 https://trial.medpath.com/news/fda-authorizes-predetermined-change-control-plan-for-sleep-wearable-dreem-3s 2024-12-03T17:01:29+00:00 weekly 0.7 https://trial.medpath.com/news/new-multi-society-guidance-most-patients-can-continue-glp-1-ras-before-endoscopic-procedures 2024-12-03T17:00:41+00:00 weekly 0.7 https://trial.medpath.com/news/trials-launch-of-nadofaragene-firadenovec-in-bladder-cancer-urology-times 2024-12-03T16:54:36+00:00 weekly 0.7 https://trial.medpath.com/news/viewpoint-closing-the-gap-in-pediatric-drug-research-missoula-current 2024-12-03T16:41:20+00:00 weekly 0.7 https://trial.medpath.com/news/university-hospitals-awarded-7-million-by-pcori-to-study-endovascular-thrombectomy-in 2024-12-03T16:25:30+00:00 weekly 0.7 https://trial.medpath.com/news/janux-impresses-wall-street-with-new-prostate-cancer-drug-results-biopharma-dive 2024-12-03T16:18:43+00:00 weekly 0.7 https://trial.medpath.com/news/lantern-pharma-shares-rise-after-fast-track-designation-for-cancer-treatment 2024-12-03T15:46:26+00:00 weekly 0.7 https://trial.medpath.com/news/perioperative-nivolumab-results-in-favourable-long-term-outcomes-in-patients-with-locally-nature 2024-12-03T15:45:33+00:00 weekly 0.7 https://trial.medpath.com/news/alligator-bioscience-s-operating-loss-increased-looking-forward-to-important-year 2024-12-03T15:45:18+00:00 weekly 0.7 https://trial.medpath.com/news/pcori-awards-unc-researcher-14-4-million-to-study-emerging-medications-for-pibd-patients 2024-12-03T15:40:15+00:00 weekly 0.7 https://trial.medpath.com/news/takeda-puts-over-1-1b-on-the-line-for-keros-blood-cancer-anemia-drug-biospace 2024-12-03T15:07:02+00:00 weekly 0.7 https://trial.medpath.com/news/active-biotech-reduces-loss-slightly-projects-progressing-according-to-plan 2024-12-03T14:52:16+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trials-in-aml-seek-to-eliminate-leftover-cells-that-persist-after-treatment 2024-12-03T14:34:58+00:00 weekly 0.7 https://trial.medpath.com/news/dana-farber-researchers-to-present-findings-at-2024-san-antonio-breast-cancer-symposium 2024-12-03T14:34:48+00:00 weekly 0.7 https://trial.medpath.com/news/chinese-bio-tech-sector-thrives-with-record-breaking-exports-and-key-fda-approvals 2024-12-03T14:16:28+00:00 weekly 0.7 https://trial.medpath.com/news/ferring-advances-three-studies-in-adstiladrin-r-nadofaragene-firadenovec-vncg 2024-12-03T14:12:40+00:00 weekly 0.7 https://trial.medpath.com/news/effects-of-initial-peritoneal-dialysis-prescription-on-clinical-outcomes-in-japanese-nature 2024-12-03T14:12:34+00:00 weekly 0.7 https://trial.medpath.com/news/wave-neuroscience-receives-fda-breakthrough-device-designation-for-pioneering-ptsd 2024-12-03T14:11:30+00:00 weekly 0.7 https://trial.medpath.com/news/va-awards-1-5-million-to-study-using-psychedelics-for-ptsd-treatment-air-force-times 2024-12-03T14:05:08+00:00 weekly 0.7 https://trial.medpath.com/news/achieve-life-sciences-gets-fda-green-light-for-landmark-vaping-cessation-drug-trial 2024-12-03T14:00:39+00:00 weekly 0.7 https://trial.medpath.com/news/amarna-therapeutics-partners-with-northx-biologics-to-advance-nimvec-am510-gene-therapy-for-type-1-diabetes 2024-12-03T14:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/gilead-plots-adc-comeback-with-potential-465m-license-agreement-biospace 2024-12-03T13:57:08+00:00 weekly 0.7 https://trial.medpath.com/news/sk-bioscience-wins-appeal-against-pfizer-in-pneumococcal-vaccine-patent-dispute 2024-12-03T13:55:25+00:00 weekly 0.7 https://trial.medpath.com/news/kairos-pharma-adds-city-of-hope-cancer-center-for-phase-2-env105-clinical-trial 2024-12-03T13:52:04+00:00 weekly 0.7 https://trial.medpath.com/news/saol-therapeutics-announces-submission-of-new-drug-application-nda-to-the-u-s-fda 2024-12-03T13:31:29+00:00 weekly 0.7 https://trial.medpath.com/news/gland-pharma-receives-us-fda-approval-for-generic-xalatan-pharmabiz-com 2024-12-03T13:21:37+00:00 weekly 0.7 https://trial.medpath.com/news/karyopharm-therapeutics-provides-endometrial-cancer-program-update-dec-3-2024 2024-12-03T13:21:10+00:00 weekly 0.7 https://trial.medpath.com/news/lantern-pharma-s-investigational-drug-candidate-lp-184-receives-second-fast-track 2024-12-03T13:18:10+00:00 weekly 0.7 https://trial.medpath.com/news/polaritybio-announces-interim-enrollment-achieved-in-skinte-s-phase-iii-pivotal-study 2024-12-03T13:14:55+00:00 weekly 0.7 https://trial.medpath.com/news/relay-therapeutics-inks-500m-licensing-deal-with-elevar-for-cancer-drug-lirafugratinib 2024-12-03T13:10:08+00:00 weekly 0.7 https://trial.medpath.com/news/pds-biotech-to-host-key-opinion-leader-event-on-december-17-globenewswire 2024-12-03T13:04:57+00:00 weekly 0.7 https://trial.medpath.com/news/cancer-survivorship-care-faces-critical-gaps-in-long-term-patient-monitoring-and-transition-management 2024-12-03T13:00:10+00:00 weekly 0.7 https://trial.medpath.com/news/kinevant-sciences-announces-topline-results-from-phase-2-resolve-lung-study-of-biospace 2024-12-03T12:58:16+00:00 weekly 0.7 https://trial.medpath.com/news/intra-cellular-therapies-submits-supplemental-new-drug-application-snda-to-fda-for 2024-12-03T12:36:41+00:00 weekly 0.7 https://trial.medpath.com/news/psyence-biomedical-advances-phase-iib-trial-doubles-psylabs-stake-value-to-2m 2024-12-03T12:34:38+00:00 weekly 0.7 https://trial.medpath.com/news/aptose-partners-with-nci-to-advance-tuspetinib-cancer-treatment-in-clinical-trials 2024-12-03T12:34:36+00:00 weekly 0.7 https://trial.medpath.com/news/merus-s-swot-analysis-innovative-antibody-stock-shows-promise-amid-clinical-trials 2024-12-03T12:29:58+00:00 weekly 0.7 https://trial.medpath.com/news/tonix-pharmaceuticals-holding-corp-filed-sec-form-8-k-regulation-fd-disclosure-other 2024-12-03T12:19:53+00:00 weekly 0.7 https://trial.medpath.com/news/key-stability-testing-milestones-achieved-for-mrx1-company-announcement-investegate 2024-12-03T12:09:42+00:00 weekly 0.7 https://trial.medpath.com/news/corbus-pharma-secures-fda-fast-track-status-for-cancer-drug-crb-701-crbp-stock-news 2024-12-03T12:05:56+00:00 weekly 0.7 https://trial.medpath.com/news/elicio-therapeutics-announces-completion-of-phase-2-amplify-7p-study-enrollment 2024-12-03T12:04:42+00:00 weekly 0.7 https://trial.medpath.com/news/valneva-reports-positive-three-year-antibody-persistence-data-for-its-single-shot 2024-12-03T12:01:50+00:00 weekly 0.7 https://trial.medpath.com/news/datroway-r-datopotamab-deruxtecan-receives-eu-approval-for-previously-treated-metastatic-hr-her2-breast-cancer 2024-12-03T11:54:30+00:00 weekly 0.7 https://trial.medpath.com/news/cartesian-advances-mg-treatment-with-phase-3-trial-plans-investing-com 2024-12-03T11:18:24+00:00 weekly 0.7 https://trial.medpath.com/news/deep-brain-stimulation-helps-two-patients-walk-after-spinal-cord-injury 2024-12-03T11:12:59+00:00 weekly 0.7 https://trial.medpath.com/news/artery-procedure-may-offer-surgery-free-way-to-ease-knee-arthritis 2024-12-03T11:12:03+00:00 weekly 0.7 https://trial.medpath.com/news/genethon-and-hansa-biopharma-announce-initiation-of-a-phase-2-trial-of-imlifidase-as-biospace 2024-12-03T11:11:57+00:00 weekly 0.7 https://trial.medpath.com/news/polyactiva-s-pa5108-glaucoma-implant-shows-promising-results-in-clinical-trial-paving-the 2024-12-03T11:09:18+00:00 weekly 0.7 https://trial.medpath.com/news/inventisbio-announces-positive-phase-2-study-results-for-d-2570-tyk2-inhibitor-in-biospace 2024-12-03T10:47:51+00:00 weekly 0.7 https://trial.medpath.com/news/can-dermata-s-dmt310-clear-the-phase-iii-acne-trial-rttnews 2024-12-03T10:46:56+00:00 weekly 0.7 https://trial.medpath.com/news/resalis-therapeutics-announces-initiation-of-phase-1-clinical-trial-for-res-010-in-obesity 2024-12-03T10:45:51+00:00 weekly 0.7 https://trial.medpath.com/news/gene-therapy-and-secondary-malignancies-integration-site-analysis-can-only-be-part-of 2024-12-03T10:30:43+00:00 weekly 0.7 https://trial.medpath.com/news/hutchmed-innovent-win-china-approval-for-breakthrough-cancer-drug-combination-stock-titan 2024-12-03T10:13:47+00:00 weekly 0.7 https://trial.medpath.com/news/japan-s-health-ministry-panel-gives-greenlight-to-new-als-drug 2024-12-03T10:02:59+00:00 weekly 0.7 https://trial.medpath.com/news/eye-cancer-breakthrough-as-nhs-roll-out-new-pioneering-drug-which-could-boost-patients 2024-12-03T09:58:29+00:00 weekly 0.7 https://trial.medpath.com/news/fda-s-ban-on-flavored-e-cigarettes-faces-supreme-court-challenge-amid-youth-protection-concerns 2024-12-03T09:54:00+00:00 weekly 0.7 https://trial.medpath.com/news/shanghai-henlius-boosts-oncology-portfolio-with-drug-approval-tipranks-com 2024-12-03T09:47:11+00:00 weekly 0.7 https://trial.medpath.com/news/sunshine-biopharma-announces-breakthrough-research-results-on-the-company-s-k1-1 2024-12-03T09:09:44+00:00 weekly 0.7 https://trial.medpath.com/news/jasper-therapeutics-announces-first-patient-dosed-in-phase-1b-2a-etesian-clinical-study 2024-12-03T08:51:39+00:00 weekly 0.7 https://trial.medpath.com/news/shockwave-medical-s-ivl-technology-still-safe-effective-in-patients-with-calcified-nodules 2024-12-03T08:42:57+00:00 weekly 0.7 https://trial.medpath.com/news/sanofi-korea-to-launch-beyfortus-for-rsv-prevention-in-infants-early-next-year-kbr 2024-12-03T08:37:37+00:00 weekly 0.7 https://trial.medpath.com/news/patient-relevant-digital-motor-outcomes-for-clinical-trials-in-hereditary-spastic-paraplegia-type-7 2024-12-03T08:06:56+00:00 weekly 0.7 https://trial.medpath.com/news/sobi-s-strength-in-haematology-to-be-showcased-at-ash-2024 2024-12-03T07:30:33+00:00 weekly 0.7 https://trial.medpath.com/news/efficacy-of-vyepti-highlighted-by-new-clinical-trial-results-in-severe-migraine-cision-news 2024-12-03T07:20:27+00:00 weekly 0.7 https://trial.medpath.com/news/simcere-s-sublingual-edaravone-nears-international-phase-iii-trial-after-china-approval 2024-12-03T07:03:38+00:00 weekly 0.7 https://trial.medpath.com/news/cdc-reports-significant-progress-in-sti-control-gonorrhea-cases-drop-7-first-major-syphilis-decline-in-20-years 2024-12-03T06:58:00+00:00 weekly 0.7 https://trial.medpath.com/news/microbiome-research-facilities-at-duchossois-family-institute-set-to-begin-drug-testing-by-january 2024-12-03T05:15:47+00:00 weekly 0.7 https://trial.medpath.com/news/jupiter-neurosciences-juns-raises-11-million-in-first-ipo-of-december-2024-iposcoop 2024-12-03T04:24:57+00:00 weekly 0.7 https://trial.medpath.com/news/precision-medicine-transforming-treatment-for-corneal-blindness-mirage-news 2024-12-03T03:21:20+00:00 weekly 0.7 https://trial.medpath.com/news/avera-to-expand-cancer-research-in-marshall-region-news-sports-jobs 2024-12-03T02:50:52+00:00 weekly 0.7 https://trial.medpath.com/news/acceptance-of-a-new-drug-application-for-the-gram-negative-bacterial-infection-treatment 2024-12-03T02:33:33+00:00 weekly 0.7 https://trial.medpath.com/news/invion-doses-first-patient-in-phase-i-ii-non-melanoma-skin-cancer-trial-inn 2024-12-03T02:29:35+00:00 weekly 0.7 https://trial.medpath.com/news/what-s-it-like-to-be-in-a-clinical-trial-abbott-newsroom 2024-12-03T02:01:32+00:00 weekly 0.7 https://trial.medpath.com/news/novelmed-receives-fda-ind-approval-for-nm8074-globenewswire 2024-12-03T01:31:39+00:00 weekly 0.7 https://trial.medpath.com/news/a-phase-2-study-of-nivolumab-and-ipilimumab-immunotherapy-with-or-without 2024-12-03T01:25:57+00:00 weekly 0.7 https://trial.medpath.com/news/ormp-preparations-for-new-phase-3-trial-advance-while-ormp-leverages-balance 2024-12-03T01:14:28+00:00 weekly 0.7 https://trial.medpath.com/news/the-landscape-of-recurrent-spontaneous-abortion-registered-on-clinical-trials-gov 2024-12-03T01:04:16+00:00 weekly 0.7 https://trial.medpath.com/news/closing-bell-asx-gallops-as-healthcare-sector-jumps-led-by-invion 2024-12-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novo-nordisk-to-present-new-data-highlighting-innovative-rare-blood 2024-12-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/diamyd-medical-secures-sek-114-million-through-rights-issue-to-advance-type-1-diabetes-therapy 2024-12-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/eu-gmp-annex-1-revision-stricter-standards-for-sterile-medicinal-products-now-in-effect 2024-12-03T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/lixte-biotechnology-inks-amendment-to-cancer-drug-study-agreement-investing-com 2024-12-02T23:44:39+00:00 weekly 0.7 https://trial.medpath.com/news/ocumension-advances-phase-iii-trials-for-key-drug-tipranks-com 2024-12-02T23:40:55+00:00 weekly 0.7 https://trial.medpath.com/news/ptc-gets-1bn-from-novartis-for-phase-ii-huntington-s-candidate-citeline 2024-12-02T23:08:22+00:00 weekly 0.7 https://trial.medpath.com/news/serina-therapeutics-secures-10m-financing-for-parkinson-s-drug-trial-at-120-premium 2024-12-02T22:35:37+00:00 weekly 0.7 https://trial.medpath.com/news/raider-trial-safety-of-tumor-directed-dose-escalation-robert-huddart-urotoday 2024-12-02T22:18:11+00:00 weekly 0.7 https://trial.medpath.com/news/study-identifies-strategies-for-racial-ethnic-diversity-in-clinical-trials-healio 2024-12-02T22:14:23+00:00 weekly 0.7 https://trial.medpath.com/news/janux-announces-doses-selected-for-phase-1b-expansion-trials-supported-by-markets-data 2024-12-02T21:51:46+00:00 weekly 0.7 https://trial.medpath.com/news/eisai-closes-door-on-lorcaserin-program-for-dravet-syndrome-neurologylive 2024-12-02T20:11:06+00:00 weekly 0.7 https://trial.medpath.com/news/gemcitabine-and-docetaxel-combination-offers-promising-alternative-to-bcg-in-bladder 2024-12-02T20:01:18+00:00 weekly 0.7 https://trial.medpath.com/news/foundation-fighting-blindness-partners-with-university-of-colorado-anschutz-medical 2024-12-02T19:51:02+00:00 weekly 0.7 https://trial.medpath.com/news/china-medical-system-gained-exclusive-commercialization-globenewswire 2024-12-02T19:43:49+00:00 weekly 0.7 https://trial.medpath.com/news/from-dogs-to-humans-ai-powered-drug-response-prediction-technology-demonstrates 2024-12-02T19:36:30+00:00 weekly 0.7 https://trial.medpath.com/news/summit-therapeutics-stock-set-to-soar-by-mid-2025-on-harmoni-phase-3-trial 2024-12-02T19:14:20+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-ptc-ink-up-to-2-9b-huntington-s-disease-collaboration 2024-12-02T19:07:20+00:00 weekly 0.7 https://trial.medpath.com/news/fox-chase-s-study-activation-unit-showcases-work-in-clinical-research-innovation-at 2024-12-02T18:53:07+00:00 weekly 0.7 https://trial.medpath.com/news/batten-1-may-preserve-vision-with-juvenile-batten-disease-scientists 2024-12-02T18:13:43+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-of-bovhyaluronidase-azoximer-raises-hopes-for-patients-with-pulmonary 2024-12-02T17:46:58+00:00 weekly 0.7 https://trial.medpath.com/news/cm24-plus-nivolumab-and-chemo-displays-efficacy-vs-chemo-alone-in-metastatic-pdac 2024-12-02T17:42:33+00:00 weekly 0.7 https://trial.medpath.com/news/intratumoral-heterogeneity-drives-acquired-therapy-resistance-in-a-patient-with-metastatic 2024-12-02T17:37:59+00:00 weekly 0.7 https://trial.medpath.com/news/year-in-review-multiple-myeloma-medpage-today 2024-12-02T17:37:10+00:00 weekly 0.7 https://trial.medpath.com/news/improving-hiv-aids-treatment-and-prevention-through-statistical-expertise 2024-12-02T17:18:10+00:00 weekly 0.7 https://trial.medpath.com/news/biotech-stocks-facing-fda-decision-in-december-2024-rttnews 2024-12-02T17:12:27+00:00 weekly 0.7 https://trial.medpath.com/news/biopharma-takes-on-deadly-brain-cancer-after-decades-of-failure-biospace 2024-12-02T17:07:39+00:00 weekly 0.7 https://trial.medpath.com/news/pain-management-collaboratory-coordinating-center-receives-grant-to-continue-research 2024-12-02T16:57:17+00:00 weekly 0.7 https://trial.medpath.com/news/abingworth-tight-lipped-on-1-5bn-clinical-trials-fund-reports-citeline 2024-12-02T16:54:23+00:00 weekly 0.7 https://trial.medpath.com/news/baseline-response-rates-inform-immunotherapy-sequencing-in-nsclc 2024-12-02T16:53:26+00:00 weekly 0.7 https://trial.medpath.com/news/oral-presentation-discussing-sozinibercept-set-for-the-annual-floretina-congress 2024-12-02T16:41:14+00:00 weekly 0.7 https://trial.medpath.com/news/loma-linda-university-children-s-hospital-receives-48000-st-baldrick-s-foundation-grant 2024-12-02T16:33:39+00:00 weekly 0.7 https://trial.medpath.com/news/novocure-device-succeeds-in-pancreatic-cancer-study-fda-sets-cytokinetics-decision-date 2024-12-02T16:10:28+00:00 weekly 0.7 https://trial.medpath.com/news/oncoc4-announces-fda-clearance-of-ind-application-for-potential-best-in-class-pd-1 2024-12-02T16:02:25+00:00 weekly 0.7 https://trial.medpath.com/news/senti-bio-s-phase-1-car-nk-data-allink-raises-42m-endpoints-news 2024-12-02T15:46:14+00:00 weekly 0.7 https://trial.medpath.com/news/milk-based-therapies-could-be-coming-this-biotech-ceo-is-aiming-to-lead-the-way 2024-12-02T15:42:37+00:00 weekly 0.7 https://trial.medpath.com/news/biotech-advances-drive-cancer-research-as-global-rates-continue-upward-trend 2024-12-02T15:39:55+00:00 weekly 0.7 https://trial.medpath.com/news/senti-bio-announces-positive-initial-clinical-data-in-phase-globenewswire 2024-12-02T15:35:27+00:00 weekly 0.7 https://trial.medpath.com/news/positive-chmp-opinion-for-the-extension-of-indication-of-palforzia-r-for-the-treatment-of-biospace 2024-12-02T15:34:01+00:00 weekly 0.7 https://trial.medpath.com/news/what-an-early-discovery-in-a-syracuse-lab-could-mean-for-late-stage-breast-cancer 2024-12-02T15:31:25+00:00 weekly 0.7 https://trial.medpath.com/news/expres2ion-announces-approval-to-initiate-a-phase-i-clinical-trial-of-es2b-c001-its-novel 2024-12-02T15:28:19+00:00 weekly 0.7 https://trial.medpath.com/news/oncolysis-immunotherapy-shows-significant-data-in-prostate-cancer 2024-12-02T15:10:07+00:00 weekly 0.7 https://trial.medpath.com/news/december-2-2024-nci-supported-lungsmart-trial-joins-the-nih-pragmatic-trials-collaboratory 2024-12-02T15:03:03+00:00 weekly 0.7 https://trial.medpath.com/news/study-reveals-divergent-cancer-drug-price-trends-us-sees-post-launch-increases-while-european-prices-decline 2024-12-02T15:00:41+00:00 weekly 0.7 https://trial.medpath.com/news/pet-ct-outcomes-from-a-randomised-controlled-trial-of-rosuvastatin-as-an-adjunct-to 2024-12-02T14:54:07+00:00 weekly 0.7 https://trial.medpath.com/news/ajax-therapeutics-to-present-overview-of-phase-1-clinical-trial-evaluating-aj1-11095-a 2024-12-02T14:52:57+00:00 weekly 0.7 https://trial.medpath.com/news/use-of-mesoglycan-in-the-acute-phase-of-hemorrhoidal-disease-the-chormes-study-trials 2024-12-02T14:30:58+00:00 weekly 0.7 https://trial.medpath.com/news/delcath-systems-announces-fda-clearance-of-ind-application-for-phase-2-clinical-trial-of 2024-12-02T14:24:24+00:00 weekly 0.7 https://trial.medpath.com/news/nervonik-completes-first-in-human-clinical-trial-of-nerve-stimulation-technology-for 2024-12-02T14:11:52+00:00 weekly 0.7 https://trial.medpath.com/news/sana-biotechnology-announces-fast-track-designation-for-globenewswire 2024-12-02T14:11:30+00:00 weekly 0.7 https://trial.medpath.com/news/new-rsv-drug-delivers-promising-results-in-alaska-s-yukon-kuskokwim-delta 2024-12-02T14:10:36+00:00 weekly 0.7 https://trial.medpath.com/news/kisoji-biotechnology-raises-41-million-to-advance-lead-program-into-the-clinic-pr-newswire 2024-12-02T14:03:46+00:00 weekly 0.7 https://trial.medpath.com/news/united-health-products-files-fda-application-for-cellustat-clinical-trial-ueec-stock-news 2024-12-02T14:02:03+00:00 weekly 0.7 https://trial.medpath.com/news/cantargia-doses-first-subject-in-expanded-part-of-can10-s-phase-i-trial 2024-12-02T13:56:22+00:00 weekly 0.7 https://trial.medpath.com/news/esperion-announces-new-drug-submissions-in-canada-for-nexletol-r-bempedoic-acid 2024-12-02T13:32:16+00:00 weekly 0.7 https://trial.medpath.com/news/rigel-announces-r289-granted-fast-track-designation-by-the-fda-for-lower-risk-mds 2024-12-02T13:30:34+00:00 weekly 0.7 https://trial.medpath.com/news/cg-oncology-to-host-conference-call-and-webcast-on-bond-003-data-on-thursday 2024-12-02T13:14:43+00:00 weekly 0.7 https://trial.medpath.com/news/uc-doctors-study-if-vaccines-can-prevent-lung-cancer-recurrence-wlwt 2024-12-02T13:12:59+00:00 weekly 0.7 https://trial.medpath.com/news/a-data-driven-approach-that-could-change-mental-healthcare-in-2025-and-beyond 2024-12-02T13:12:51+00:00 weekly 0.7 https://trial.medpath.com/news/cytokinetics-announces-fda-acceptance-of-new-drug-globenewswire 2024-12-02T13:08:10+00:00 weekly 0.7 https://trial.medpath.com/news/revolution-medicines-reports-progress-in-cancer-drug-trials-investing-com 2024-12-02T13:08:05+00:00 weekly 0.7 https://trial.medpath.com/news/briacell-s-phase-3-cancer-trial-clears-key-safety-review-for-breast-cancer-treatment-stock-titan 2024-12-02T13:03:38+00:00 weekly 0.7 https://trial.medpath.com/news/ocular-therapeutixtm-announces-more-than-300-subjects-randomized-in-sol-1 2024-12-02T12:50:39+00:00 weekly 0.7 https://trial.medpath.com/news/medicus-pharma-expands-bcc-treatment-trial-to-asia-pacific-after-promising-phase-1-results 2024-12-02T12:50:36+00:00 weekly 0.7 https://trial.medpath.com/news/zai-lab-novocure-report-positive-topline-results-from-phase-3-panova-3-trial-of-rttnews 2024-12-02T12:46:38+00:00 weekly 0.7 https://trial.medpath.com/news/xoma-royalty-acquires-pulmokine-for-20m-adds-phase-3-pah-drug-to-portfolio 2024-12-02T12:43:08+00:00 weekly 0.7 https://trial.medpath.com/news/hybrytetm-clinical-results-demonstrate-continued-improvement-post-treatment-pr-newswire 2024-12-02T12:37:15+00:00 weekly 0.7 https://trial.medpath.com/news/medexus-amends-treosulfan-deal-100m-revenue-target-fda-milestone-payments-up-to-45m 2024-12-02T12:07:32+00:00 weekly 0.7 https://trial.medpath.com/news/olema-oncology-lands-250m-funding-novartis-partnership-for-cancer-drug-trial 2024-12-02T12:05:31+00:00 weekly 0.7 https://trial.medpath.com/news/revelation-biosciences-inc-announces-fda-acceptance-of-gemini-ind-stock-titan 2024-12-02T11:10:36+00:00 weekly 0.7 https://trial.medpath.com/news/molecular-testing-drives-personalized-treatment-approaches-in-endometrial-cancer 2024-12-02T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-hiv-cure-trial-targets-women-in-kzn-the-witness 2024-12-02T10:20:49+00:00 weekly 0.7 https://trial.medpath.com/news/a-feasibility-study-using-quantitative-and-interpretable-histological-analyses-of-celiac-disease 2024-12-02T09:45:19+00:00 weekly 0.7 https://trial.medpath.com/news/medicare-s-first-drug-price-negotiations-yield-mixed-results-u-s-prices-still-exceed-international-levels 2024-12-02T08:24:25+00:00 weekly 0.7 https://trial.medpath.com/news/interactions-with-uk-regulatory-authorities-faron-pharmaceuticals-oy-cision-news 2024-12-02T08:10:23+00:00 weekly 0.7 https://trial.medpath.com/news/capsule-sponge-test-revolutionizes-gerd-diagnosis-reduces-unnecessary-endoscopies 2024-12-02T07:34:02+00:00 weekly 0.7 https://trial.medpath.com/news/global-biotechnology-market-projected-to-reach-usd-3-54-trillion-by-2033-driven-by-therapeutic-innovations 2024-12-02T07:20:45+00:00 weekly 0.7 https://trial.medpath.com/news/deepull-receives-fda-breakthrough-device-designation-for-its-ullcore-bloodstream-infection-test 2024-12-02T07:11:29+00:00 weekly 0.7 https://trial.medpath.com/news/aavantgarde-bio-announces-fda-orphan-drug-designation-for-globenewswire 2024-12-02T07:11:29+00:00 weekly 0.7 https://trial.medpath.com/news/sparsentan-receives-orphan-drug-designation-for-primary-iga-nephropathy-in-japan 2024-12-02T06:48:04+00:00 weekly 0.7 https://trial.medpath.com/news/nicox-s-denali-phase-3-trial-of-ncx-470-fully-enrolled-in-china-earlier-than-expected 2024-12-02T06:39:43+00:00 weekly 0.7 https://trial.medpath.com/news/hk-inno-n-s-gerd-drug-k-cab-recommended-for-approval-in-india-kbr 2024-12-02T05:47:50+00:00 weekly 0.7 https://trial.medpath.com/news/orum-therapeutics-withdraws-from-ipo-citing-difficulties-in-fair-valuation-kbr 2024-12-02T02:54:31+00:00 weekly 0.7 https://trial.medpath.com/news/preliminary-adaptation-of-cognitive-behavioral-therapy-for-major-depression-in-bmc-psychiatry 2024-12-02T02:36:02+00:00 weekly 0.7 https://trial.medpath.com/news/effect-of-fecal-microbiota-transplantation-on-patients-with-sporadic-amyotrophic-lateral-sclerosis 2024-12-02T02:29:32+00:00 weekly 0.7 https://trial.medpath.com/news/quabodepistat-combo-shows-promise-for-safer-faster-tuberculosis-treatment-news-medical 2024-12-02T00:17:36+00:00 weekly 0.7 https://trial.medpath.com/news/home-sapience-therapeutics 2024-12-02T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/why-this-asx-healthcare-share-is-soaring-26-on-study-findings-motley-fool 2024-12-01T23:52:42+00:00 weekly 0.7 https://trial.medpath.com/news/everest-medicines-announces-acceptance-of-velsipity-r-new-drug-application-in-hong-kong 2024-12-01T23:44:01+00:00 weekly 0.7 https://trial.medpath.com/news/orthocell-ever-closer-to-us-remplirtm-launch-as-it-wraps-up-regulatory-study-for-fda-clearance 2024-12-01T23:23:05+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-study-in-hk-confirms-singapore-s-bixeps-machine-improves-muscle-strength 2024-12-01T21:01:17+00:00 weekly 0.7 https://trial.medpath.com/news/ongoing-clinical-trial-shows-very-promising-results-using-eye-implant-to-treat-macular 2024-12-01T20:51:04+00:00 weekly 0.7 https://trial.medpath.com/news/endocrinology-month-in-review-november-2024-hcplive 2024-12-01T20:04:06+00:00 weekly 0.7 https://trial.medpath.com/news/evaluating-covid-19-vaccination-safety-in-multiple-sclerosis 2024-12-01T19:32:22+00:00 weekly 0.7 https://trial.medpath.com/news/dangerous-food-allergy-reactions-a-drug-free-life 2024-12-01T19:25:38+00:00 weekly 0.7 https://trial.medpath.com/news/higher-dose-of-nusinersen-shows-greater-impact-on-spinal-muscular-atrophy-in-phase-2-3 2024-12-01T17:14:09+00:00 weekly 0.7 https://trial.medpath.com/news/merus-s-petosemtamab-shows-40-4-response-rate-in-head-neck-cancer-trial 2024-12-01T16:19:35+00:00 weekly 0.7 https://trial.medpath.com/news/hepb-cpg-vs-hepb-alum-vaccine-in-people-with-hiv-and-prior-vaccine-nonresponse 2024-12-01T16:19:25+00:00 weekly 0.7 https://trial.medpath.com/news/fda-permits-using-johnson-johnson-cancer-drug-without-chemo 2024-12-01T16:19:08+00:00 weekly 0.7 https://trial.medpath.com/news/jazz-pharmaceuticals-jazz-is-making-sweet-music-with-a-diverse-portfolio-tipranks 2024-12-01T15:46:54+00:00 weekly 0.7 https://trial.medpath.com/news/lactated-ringer-s-a-clear-winner-for-pancreatitis-resuscitation-emergency-medicine-news 2024-12-01T15:40:50+00:00 weekly 0.7 https://trial.medpath.com/news/drug-topics-top-10-most-read-stories-from-november-2024 2024-12-01T15:03:57+00:00 weekly 0.7 https://trial.medpath.com/news/sidra-medicine-conducts-first-clinical-trial-for-pediatric-congenital-hyperinsulinism 2024-12-01T13:01:16+00:00 weekly 0.7 https://trial.medpath.com/news/new-diabetes-treatment-delays-onset-of-type-1-diabetes-uh-treats-first-ne-ohio-patient 2024-12-01T12:06:39+00:00 weekly 0.7 https://trial.medpath.com/news/aasm-updates-restless-legs-syndrome-treatment-guidelines-shifts-away-from-dopamine-agonists 2024-12-01T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/aav-delivery-strategy-with-mechanical-support-for-safe-and-efficacious-cardiac-gene-transfer-in-swine 2024-12-01T09:33:40+00:00 weekly 0.7 https://trial.medpath.com/news/a-twice-yearly-shot-could-help-end-aids-bangladesh-unb 2024-12-01T09:17:07+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-fda-approves-biocon-biologics-yesintektm-bmab-1200-biosimilar-to-j-j-s-stelara 2024-12-01T08:57:04+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-hiv-prevention-shot-faces-global-access-challenges-health-devdiscourse 2024-12-01T06:12:41+00:00 weekly 0.7 https://trial.medpath.com/news/2025-trends-buoying-boom-phase-in-apac-biospectrum-asia 2024-12-01T05:24:18+00:00 weekly 0.7 https://trial.medpath.com/news/kidney-failure-was-the-third-fastest-growing-cause-of-death-in-2023-exacerbated-by-the-lack 2024-12-01T05:19:55+00:00 weekly 0.7 https://trial.medpath.com/news/graft-versus-host-disease-pipeline-therapeutics-assessment-report-2024-updated-openpr-com 2024-12-01T05:01:14+00:00 weekly 0.7 https://trial.medpath.com/news/hiv-prevention-remains-elusive-biospectrum-india 2024-12-01T02:51:41+00:00 weekly 0.7 https://trial.medpath.com/news/zydus-cadila-begins-enrolment-for-phase-3-vaccine-trial-reports-inshorts 2024-12-01T02:43:02+00:00 weekly 0.7 https://trial.medpath.com/news/moderna-inc-mrna-a-bull-case-theory-yahoo-finance 2024-12-01T00:10:26+00:00 weekly 0.7 https://trial.medpath.com/news/prevalence-and-profiles-of-treatment-related-adverse-events-in-metastatic-breast-cancer-patients-receiving-antibody-drug-conjugates 2024-12-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/efficacy-and-safety-of-gene-therapy-with-onasemnogene 2024-12-01T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/praxis-precision-medicines-to-showcase-updates-from-pipeline-of-epilepsy-pharmabiz-com 2024-11-30T23:30:51+00:00 weekly 0.7 https://trial.medpath.com/news/arvin-k-george-md-provides-update-on-the-preserve-trial-urology-times 2024-11-30T23:04:10+00:00 weekly 0.7 https://trial.medpath.com/news/vcu-startup-grabs-military-attention-funding-virginia-business 2024-11-30T21:56:13+00:00 weekly 0.7 https://trial.medpath.com/news/applied-therapeutics-crl-a-major-setback-says-william-blair-yahoo-finance 2024-11-30T21:50:05+00:00 weekly 0.7 https://trial.medpath.com/news/an-introduction-to-ananda-developments-share-talk 2024-11-30T20:55:04+00:00 weekly 0.7 https://trial.medpath.com/news/trem-1-and-trem-2-as-therapeutic-targets-clinical-challenges-and-perspectives 2024-11-30T19:54:52+00:00 weekly 0.7 https://trial.medpath.com/news/zai-lab-announces-the-inclusion-of-augtyro-for-ros1-nsclc-and-other-updates-in-china-s 2024-11-30T19:30:40+00:00 weekly 0.7 https://trial.medpath.com/news/hua-medicine-announces-successful-u-s-phase-i-results-on-its-2nd-generation-gka-candidate 2024-11-30T19:18:41+00:00 weekly 0.7 https://trial.medpath.com/news/effectiveness-of-photobiomodulation-with-low-level-lasers-on-the-acceleration-of-orthodontic 2024-11-30T19:05:33+00:00 weekly 0.7 https://trial.medpath.com/news/medical-breakthrough-or-temporary-fix-the-brutal-truth-about-weight-loss-medications 2024-11-30T19:03:44+00:00 weekly 0.7 https://trial.medpath.com/news/phase-2-galactic53-data-point-to-viltolarsen-s-impact-on-respiratory-and-motor-function-in-dmd 2024-11-30T16:08:58+00:00 weekly 0.7 https://trial.medpath.com/news/new-cpx-351-data-underscore-complexity-of-treating-aml-in-older-patients 2024-11-30T16:08:46+00:00 weekly 0.7 https://trial.medpath.com/news/deuruxolitinib-demonstrates-efficacy-safety-in-adults-with-alopecia-areata 2024-11-30T16:08:46+00:00 weekly 0.7 https://trial.medpath.com/news/b-c-man-calls-for-federal-government-to-cover-costly-life-saving-cancer-treatment-cbc 2024-11-30T15:08:06+00:00 weekly 0.7 https://trial.medpath.com/news/first-patient-dosed-in-study-assessing-immunotherapy-in-metastatic-breast-cancer 2024-11-30T15:02:24+00:00 weekly 0.7 https://trial.medpath.com/news/india-takes-centre-stage-in-clinical-trials-for-hiv-aids-drug-drugscontrol-media-services 2024-11-30T14:36:42+00:00 weekly 0.7 https://trial.medpath.com/news/how-a-landmark-uc-davis-health-clinical-trial-to-treat-spina-bifida-gave-one-roseville-family-hope 2024-11-30T13:41:42+00:00 weekly 0.7 https://trial.medpath.com/news/biotech-stock-roundup-bbio-stock-up-on-drug-approval-sava-aplt-plunge-on-setbacks-more 2024-11-30T13:39:42+00:00 weekly 0.7 https://trial.medpath.com/news/hua-medicine-announces-successful-h-k-sensitize-study-results-at-the-cbiic 2024-11-30T12:46:38+00:00 weekly 0.7 https://trial.medpath.com/news/warning-this-skyrocketing-stock-has-a-hidden-risk-the-globe-and-mail 2024-11-30T11:52:20+00:00 weekly 0.7 https://trial.medpath.com/news/chronic-hand-eczema-november-2024-supplement-recap-dermatology-times 2024-11-30T11:46:13+00:00 weekly 0.7 https://trial.medpath.com/news/i-m-a-dementia-expert-who-spent-25-years-caring-for-patients-now-i-ve-been-diagnosed 2024-11-30T11:39:01+00:00 weekly 0.7 https://trial.medpath.com/news/ucla-researchers-engineer-experimental-drug-for-preventing-heart-failure-after-heart-attacks 2024-11-30T11:22:35+00:00 weekly 0.7 https://trial.medpath.com/news/oragenics-announces-termination-of-president-s-employment-agreement-investing-com 2024-11-30T09:19:55+00:00 weekly 0.7 https://trial.medpath.com/news/lumosa-therapeutics-co-ltd-announces-the-unblinded-analysis-results-from-phase-ii 2024-11-30T07:41:45+00:00 weekly 0.7 https://trial.medpath.com/news/bcma-car-t-therapy-combined-with-pomalidomide-is-a-safe-and-effective-treatment-for 2024-11-30T07:40:53+00:00 weekly 0.7 https://trial.medpath.com/news/bevacizumab-versus-aflibercept-with-folfiri-after-folfox-and-bevacizumab-in-ras-nature 2024-11-30T07:05:32+00:00 weekly 0.7 https://trial.medpath.com/news/q-a-pharmacist-on-medication-developments-for-people-living-with-hiv-drug-topics 2024-11-30T06:32:21+00:00 weekly 0.7 https://trial.medpath.com/news/global-cancer-care-crisis-study-reveals-widening-treatment-access-gap-between-rich-and-poor-nations 2024-11-30T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/concizumab-reduces-bleeding-in-patients-without-inhibitors-hemophilia-news-today 2024-11-30T05:09:28+00:00 weekly 0.7 https://trial.medpath.com/news/dr-schmid-on-pembrolizumab-plus-chemotherapy-in-high-risk-early-stage-tnbc 2024-11-30T04:04:52+00:00 weekly 0.7 https://trial.medpath.com/news/new-ppar-agonists-expand-treatment-landscape-for-primary-biliary-cholangitis 2024-11-30T02:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/mirum-plans-2025-phase-2-trial-testing-fragile-x-treatment 2024-11-29T21:38:39+00:00 weekly 0.7 https://trial.medpath.com/news/navitoclax-and-ruxolitinib-show-potential-in-treating-r-r-myelofibrosis-pharmacy-times 2024-11-29T21:04:21+00:00 weekly 0.7 https://trial.medpath.com/news/effectiveness-of-probiotics-prebiotics-and-synbiotics-in-managing-insulin-resistance-pubmed 2024-11-29T20:09:54+00:00 weekly 0.7 https://trial.medpath.com/news/neurologylive-r-friday-5-november-29-2024 2024-11-29T20:08:34+00:00 weekly 0.7 https://trial.medpath.com/news/medmira-reports-fy2024-fourth-quarter-and-year-end-financial-results-biospace 2024-11-29T18:49:37+00:00 weekly 0.7 https://trial.medpath.com/news/apogee-therapeutics-announces-agenda-for-virtual-r-d-day-morningstar 2024-11-29T18:15:15+00:00 weekly 0.7 https://trial.medpath.com/news/polypid-announces-receipt-of-nasdaq-notification-of-minimum-globenewswire 2024-11-29T18:09:47+00:00 weekly 0.7 https://trial.medpath.com/news/biotech-raises-11m-to-advance-regenerative-osteoarthritis-drug-into-phase-3 2024-11-29T17:48:55+00:00 weekly 0.7 https://trial.medpath.com/news/mushroom-drug-statistics-2024-by-best-compound-market-us-media 2024-11-29T17:42:04+00:00 weekly 0.7 https://trial.medpath.com/news/jssstu-and-in-space-launch-jnanam-student-satellite-project-mysuru-news 2024-11-29T17:41:21+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-dr-betz-s-vertebral-body-replacement-device-orthopedics-this-week 2024-11-29T17:30:47+00:00 weekly 0.7 https://trial.medpath.com/news/high-cholesterol-linked-to-ms-cognitive-impairment-in-study-multiple-sclerosis-news-today 2024-11-29T15:55:34+00:00 weekly 0.7 https://trial.medpath.com/news/medtronic-reports-outcomes-from-aortic-stenosis-treatment-study-of-tavr-system 2024-11-29T15:47:29+00:00 weekly 0.7 https://trial.medpath.com/news/association-between-red-cell-distribution-width-and-30-day-mortality-in-patients-with-frontiers 2024-11-29T15:41:58+00:00 weekly 0.7 https://trial.medpath.com/news/advent-of-ponatinib-for-ph-all-expected-to-influence-new-guidelines 2024-11-29T15:33:35+00:00 weekly 0.7 https://trial.medpath.com/news/cell-therapy-weekly-first-patient-dosed-in-cardiac-gene-therapy-trial-regmednet 2024-11-29T15:20:26+00:00 weekly 0.7 https://trial.medpath.com/news/epi-pen-alternative-now-available-in-the-mid-state-wsmv 2024-11-29T14:43:09+00:00 weekly 0.7 https://trial.medpath.com/news/uk-s-clinical-trials-diversity-draft-gets-over-200-stakeholder-responses 2024-11-29T14:38:20+00:00 weekly 0.7 https://trial.medpath.com/news/when-the-body-attacks-itself-cu-anschutz-medical-campus 2024-11-29T14:27:44+00:00 weekly 0.7 https://trial.medpath.com/news/elacestrant-shows-significant-pfs-benefit-in-esr1-mutated-metastatic-breast-cancer 2024-11-29T14:11:30+00:00 weekly 0.7 https://trial.medpath.com/news/vznkul-nmibc-quality-indicators-program-a-flemish-prospective-cohort-to-evaluate-the 2024-11-29T14:11:29+00:00 weekly 0.7 https://trial.medpath.com/news/micurx-successfully-completes-phase-iii-clinical-trial-of-mrx-4-for-injection-in-china 2024-11-29T14:09:07+00:00 weekly 0.7 https://trial.medpath.com/news/mathematical-modeling-framework-enhances-clinical-trial-design-for-maintenance-treatment 2024-11-29T14:07:58+00:00 weekly 0.7 https://trial.medpath.com/news/scientists-identify-drug-resistant-bone-marrow-cells-linked-to-poor-outcomes-in-fast-growing-leukemia 2024-11-29T13:57:52+00:00 weekly 0.7 https://trial.medpath.com/news/coventry-hospital-in-world-first-cancer-scanner-trial-bbc 2024-11-29T13:43:37+00:00 weekly 0.7 https://trial.medpath.com/news/nuhcs-to-start-using-breakthrough-drug-for-rare-lung-condition-healthcare-asia-magazine 2024-11-29T13:43:09+00:00 weekly 0.7 https://trial.medpath.com/news/mirikizumab-effective-in-crohn-s-disease-after-initial-standard-therapy-failure 2024-11-29T13:41:23+00:00 weekly 0.7 https://trial.medpath.com/news/minghui-pharmaceutical-announces-positive-topline-results-from-phase-iii-trial-of-mh004 2024-11-29T13:33:40+00:00 weekly 0.7 https://trial.medpath.com/news/china-focus-weight-loss-drug-a-new-option-to-combat-obesity-in-china-xinhua 2024-11-29T13:29:47+00:00 weekly 0.7 https://trial.medpath.com/news/nanozymes-unlocking-next-generation-anti-inflammatory-treatments-nature 2024-11-29T13:27:45+00:00 weekly 0.7 https://trial.medpath.com/news/vabysmo-hopes-to-ride-new-coverage-in-china-data-to-expand-in-asia-citeline 2024-11-29T13:27:17+00:00 weekly 0.7 https://trial.medpath.com/news/takeda-canada-co-sponsors-grant-to-boost-ibd-clinical-research-yahoo-finance 2024-11-29T13:13:41+00:00 weekly 0.7 https://trial.medpath.com/news/3-penny-stocks-ready-to-break-out-in-2025-entrepreneur 2024-11-29T13:12:31+00:00 weekly 0.7 https://trial.medpath.com/news/silo-pharma-partners-with-kymanox-to-develop-novel-ketamine-implant-device-stock-titan 2024-11-29T13:11:51+00:00 weekly 0.7 https://trial.medpath.com/news/a-new-era-for-pancreatic-cancer-research-royal-free-london-nhs-foundation-trust 2024-11-29T13:01:42+00:00 weekly 0.7 https://trial.medpath.com/news/abbv-3-healthcare-stocks-leading-the-fight-against-global-diseases-stocknews-com 2024-11-29T12:53:54+00:00 weekly 0.7 https://trial.medpath.com/news/gene-and-cell-therapies-targeting-cns-disorders-treatment-market-2034-the-globe-and-mail 2024-11-29T12:53:34+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-spots-preston-man-s-potentially-cancerous-polyp-pharmiweb-com 2024-11-29T12:22:56+00:00 weekly 0.7 https://trial.medpath.com/news/hepatic-encephalopathy-clinical-trials-2024-ema-pdma-fda-openpr-com 2024-11-29T12:22:04+00:00 weekly 0.7 https://trial.medpath.com/news/nanexa-ab-phase-i-results-position-nex-22-for-licensing-opportunities-and-a-head-start-placera 2024-11-29T12:14:44+00:00 weekly 0.7 https://trial.medpath.com/news/propionic-acid-impact-on-multiple-sclerosis-evidence-and-challenges-pubmed 2024-11-29T12:09:46+00:00 weekly 0.7 https://trial.medpath.com/news/addyi-sex-drive-pill-for-women-that-s-fda-approved 2024-11-29T11:44:47+00:00 weekly 0.7 https://trial.medpath.com/news/relapse-in-ocular-tuberculosis-study-reveals-one-third-of-cases-resurface-after-treatment 2024-11-29T11:19:16+00:00 weekly 0.7 https://trial.medpath.com/news/radnet-s-deephealth-subsidiary-expands-fda-clearance-for-smartmammotm-solution 2024-11-29T11:11:34+00:00 weekly 0.7 https://trial.medpath.com/news/lupin-gains-tentative-usfda-nod-for-sitagliptin-and-metformin-hydrochloride-tablets 2024-11-29T10:34:10+00:00 weekly 0.7 https://trial.medpath.com/news/sponsored-gi-genius-enters-naiad-large-scale-clinical-trial-health-tech-world 2024-11-29T10:03:20+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-data-and-patient-centered-care-reshape-modern-oncology-treatment-approaches 2024-11-29T10:01:00+00:00 weekly 0.7 https://trial.medpath.com/news/kane-biotech-announces-third-quarter-2024-financial-results 2024-11-29T09:58:39+00:00 weekly 0.7 https://trial.medpath.com/news/ananda-aiming-to-meet-regulators-at-their-point-of-need-as-it-secures-more-major-uk 2024-11-29T09:49:08+00:00 weekly 0.7 https://trial.medpath.com/news/comprehensive-insight-into-lichen-planus-pipeline-landscape-revealed-for-2024 2024-11-29T09:46:21+00:00 weekly 0.7 https://trial.medpath.com/news/limb-girdle-muscular-dystrophy-lgmd-competitive-landscape-report-2024 2024-11-29T09:36:01+00:00 weekly 0.7 https://trial.medpath.com/news/ema-launches-digital-platform-to-combat-drug-shortages-across-european-union 2024-11-29T09:23:37+00:00 weekly 0.7 https://trial.medpath.com/news/china-makes-breakthrough-in-xenotransplantation-with-gene-edited-pig-kidney-surviving 2024-11-29T09:19:35+00:00 weekly 0.7 https://trial.medpath.com/news/evidentiary-basis-of-the-first-regulatory-qualification-of-a-digital-primary-efficacy-endpoint 2024-11-29T09:06:37+00:00 weekly 0.7 https://trial.medpath.com/news/study-reveals-10-distinct-cellular-neighborhoods-in-pancreatic-cancer-opening-new-treatment-pathways 2024-11-29T09:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/will-neumora-therapeutics-upcoming-data-catalysts-drive-stock-performance 2024-11-29T08:56:23+00:00 weekly 0.7 https://trial.medpath.com/news/agile-monitoring-dashboard-for-clinical-research-studies-trials-biomed-central 2024-11-29T08:29:26+00:00 weekly 0.7 https://trial.medpath.com/news/study-links-long-term-tattoo-exposure-to-increased-risk-of-rare-b-cell-lymphomas 2024-11-29T07:39:00+00:00 weekly 0.7 https://trial.medpath.com/news/lanchi-ventures-leads-42m-series-a-financing-for-allink-biotherapeutics-to-accelerate 2024-11-29T07:15:00+00:00 weekly 0.7 https://trial.medpath.com/news/ochsner-lsu-health-surgeon-successfully-performs-new-procedure-that-marks-a 2024-11-29T06:30:20+00:00 weekly 0.7 https://trial.medpath.com/news/expert-urges-integration-of-novel-therapies-and-patient-education-in-multiple-myeloma-treatment 2024-11-29T06:21:00+00:00 weekly 0.7 https://trial.medpath.com/news/global-rare-disease-drug-market-sees-promising-growth-amid-complex-access-challenges 2024-11-29T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/uk-launches-historic-national-men-s-health-strategy-to-address-critical-health-disparities 2024-11-29T04:27:09+00:00 weekly 0.7 https://trial.medpath.com/news/nefecon-r-included-in-national-reimbursement-drug-list-nrdl-jcn-newswire 2024-11-29T04:06:28+00:00 weekly 0.7 https://trial.medpath.com/news/pharma-stock-in-focus-after-it-launches-india-s-first-neck-head-cancer-treatment-drug 2024-11-29T04:03:34+00:00 weekly 0.7 https://trial.medpath.com/news/bharath-advanced-therapeutics-bat-and-faba-present-cancer-next-2024 2024-11-29T03:55:13+00:00 weekly 0.7 https://trial.medpath.com/news/revolutionary-pace-system-transforms-clinical-trial-drug-manufacturing-at-cpi-s-innovation-centre 2024-11-29T03:01:18+00:00 weekly 0.7 https://trial.medpath.com/news/do-biosimilar-monoclonal-antibodies-perform-as-well-as-the-original-medicine-for-cancer-treatment 2024-11-29T02:30:01+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-landscape-for-histone-deacetylation-inhibitors-in-breast-cancer-a-dawn-in-the-darkness 2024-11-29T01:53:58+00:00 weekly 0.7 https://trial.medpath.com/news/medytox-secures-thai-fda-approval-for-hyaluronic-acid-filler-atiere-pharma-article-kbr 2024-11-29T01:50:12+00:00 weekly 0.7 https://trial.medpath.com/news/cell-therapy-company-just-acquired-by-roche-for-us-1-5bn-ala-looks-similar 2024-11-29T01:22:43+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-data-demonstrate-efficacy-of-beti-cel-gene-therapy 2024-11-29T01:18:44+00:00 weekly 0.7 https://trial.medpath.com/news/major-ai-healthcare-breakthroughs-from-surgical-training-to-clinical-trial-matching 2024-11-29T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/counting-blessings-is-key-to-living-with-cancer-cure-today 2024-11-29T00:17:27+00:00 weekly 0.7 https://trial.medpath.com/news/resmetirom-shows-promise-in-treating-nash-mash-through-clinical-trials 2024-11-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/meta-analysis-confirms-immunotherapy-improves-overall-survival-in-head-and-neck-squamous-cell-carcinoma 2024-11-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/iwilfin-eflornithine-approved-by-the-fda-as-the-first-and 2024-11-29T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/uk-grants-promising-innovative-medicine-status-to-cidp-drug-pharmatimes 2024-11-28T23:51:23+00:00 weekly 0.7 https://trial.medpath.com/news/follicular-lymphoma-clinical-trial-pipeline-appears-robust-with-50-key-pharma 2024-11-28T23:47:52+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-cream-nears-for-skin-cancer-treatment-mirage-news 2024-11-28T23:37:02+00:00 weekly 0.7 https://trial.medpath.com/news/why-some-people-don-t-lose-weight-with-wegovy-the-conversation 2024-11-28T23:10:04+00:00 weekly 0.7 https://trial.medpath.com/news/urogen-reports-long-term-data-from-study-of-jelmyto-for-lg-utuc-treatment 2024-11-28T22:25:08+00:00 weekly 0.7 https://trial.medpath.com/news/kras-inhibitor-market-size-share-cagr-of-5-6 2024-11-28T22:18:22+00:00 weekly 0.7 https://trial.medpath.com/news/exelixis-updates-from-snda-for-cabozantinib-to-treat-patients-with-previously-treated-pharmabiz 2024-11-28T22:01:38+00:00 weekly 0.7 https://trial.medpath.com/news/derry-researchers-make-breakthrough-in-early-diagnosis-of-chronic-kidney-disease-and-covid-19 2024-11-28T21:57:43+00:00 weekly 0.7 https://trial.medpath.com/news/expert-explores-the-expanding-applications-of-glp1-therapies-news-medical 2024-11-28T21:10:04+00:00 weekly 0.7 https://trial.medpath.com/news/landmark-pill-on-a-thread-cancer-screening-trial-welcomes-first-participants 2024-11-28T20:46:40+00:00 weekly 0.7 https://trial.medpath.com/news/lot-riding-on-igi-s-promising-trispecific-antibody-for-myeloma-citeline 2024-11-28T19:48:42+00:00 weekly 0.7 https://trial.medpath.com/news/largest-uk-dairy-co-op-testing-methane-suppressing-drug-on-cattle-herds 2024-11-28T19:43:30+00:00 weekly 0.7 https://trial.medpath.com/news/sellas-announces-positive-data-from-preclinical-studies-indicating-asxl1-mutations-biospace 2024-11-28T18:24:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approved-diabetes-drug-significantly-slows-down-aging-the-brighter-side-of-news 2024-11-28T18:12:06+00:00 weekly 0.7 https://trial.medpath.com/news/formycon-reports-nine-month-results-for-2024-and-continues-growth-trajectory-with-further 2024-11-28T17:36:13+00:00 weekly 0.7 https://trial.medpath.com/news/hemophilia-b-clinical-trials-2024-ema-pdma-fda-approvals-openpr-com 2024-11-28T17:35:47+00:00 weekly 0.7 https://trial.medpath.com/news/france-approves-single-dose-vaccine-johnson-johnson 2024-11-28T17:25:03+00:00 weekly 0.7 https://trial.medpath.com/news/cervomed-s-stock-rises-as-fda-grants-orphan-drug-status-to-dementia-drug 2024-11-28T17:19:24+00:00 weekly 0.7 https://trial.medpath.com/news/outlook-holds-out-hope-for-wet-amd-approval-despite-phase-iii-topline-miss-citeline 2024-11-28T17:11:59+00:00 weekly 0.7 https://trial.medpath.com/news/targeting-rett-syndrome-at-the-source-drug-discovery-news 2024-11-28T17:09:59+00:00 weekly 0.7 https://trial.medpath.com/news/correcting-and-replacing-altasciences-supports-metsera-in-their-early-stage 2024-11-28T16:48:07+00:00 weekly 0.7 https://trial.medpath.com/news/moving-beyond-immunoglobulin-therapy-for-cidp-with-efgartigimod-nature 2024-11-28T16:27:45+00:00 weekly 0.7 https://trial.medpath.com/news/sequana-medical-s-dsr-2-0-outperforms-traditional-peritoneal-dialysis-solutions-in-study 2024-11-28T16:25:12+00:00 weekly 0.7 https://trial.medpath.com/news/merryman-discusses-the-role-of-mrd-in-lymphoma-care-and-trials-targeted-oncology 2024-11-28T16:01:27+00:00 weekly 0.7 https://trial.medpath.com/news/very-low-doses-of-rituximab-in-autoimmune-hemolytic-anemia-an-open-label-phase-ii-pilot-trial 2024-11-28T15:44:26+00:00 weekly 0.7 https://trial.medpath.com/news/sonia-trial-demonstrates-cost-effective-treatment-approach-for-advanced-breast-cancer 2024-11-28T15:17:51+00:00 weekly 0.7 https://trial.medpath.com/news/oral-anticoagulation-in-patients-with-atrial-fibrillation-and-advanced-chronic-kidney-disease 2024-11-28T15:17:14+00:00 weekly 0.7 https://trial.medpath.com/news/six-antisense-oligonucleotide-companies-shaping-the-future-of-genetic-medicine 2024-11-28T14:01:33+00:00 weekly 0.7 https://trial.medpath.com/news/truqap-emerges-as-new-hope-for-treating-hr-her2-breast-cancer-kbr 2024-11-28T13:19:05+00:00 weekly 0.7 https://trial.medpath.com/news/targeting-il-12-safely-with-intraperitoneal-therapy-represents-key-step-forward-in-ovarian-cancer 2024-11-28T13:07:07+00:00 weekly 0.7 https://trial.medpath.com/news/new-eu-filings-pink-sheet-key-regulatory-and-policy-insights 2024-11-28T12:59:56+00:00 weekly 0.7 https://trial.medpath.com/news/how-to-heal-the-pathology-of-brain-circuitry-with-a-wearable-take-home-device-to-treat-depression 2024-11-28T12:49:12+00:00 weekly 0.7 https://trial.medpath.com/news/complicated-urinary-tract-infection-uti-clinical-trials-openpr-com 2024-11-28T12:30:04+00:00 weekly 0.7 https://trial.medpath.com/news/moving-towards-more-personalized-approaches-in-locally-advanced-and-metastatic-colorectal-cancer 2024-11-28T12:28:05+00:00 weekly 0.7 https://trial.medpath.com/news/fasenra-shows-benefit-in-acute-asthma-and-copd-in-phase-ii-trial-yahoo-finance 2024-11-28T12:19:20+00:00 weekly 0.7 https://trial.medpath.com/news/anocca-submits-application-to-ema-for-pancreatic-cancer-trial 2024-11-28T11:59:45+00:00 weekly 0.7 https://trial.medpath.com/news/the-screening-and-anti-raji-lymphoma-effect-of-chiloscyllium-plagiosum-anti-cd20-vnar 2024-11-28T11:58:08+00:00 weekly 0.7 https://trial.medpath.com/news/characterizing-the-pharmacological-interaction-of-the-antimalarial-combination-artefenomel 2024-11-28T11:38:58+00:00 weekly 0.7 https://trial.medpath.com/news/allocation-and-validation-of-the-second-revision-of-the-international-staging-system-in-the-nature 2024-11-28T11:11:11+00:00 weekly 0.7 https://trial.medpath.com/news/peter-j-weiden-md-discusses-clozapine-rems-challenges-and-advisory-committees 2024-11-28T10:47:09+00:00 weekly 0.7 https://trial.medpath.com/news/fda-announces-probe-into-bluebird-s-elivaldogene-autotemcel-for-hematologic-malignancies 2024-11-28T10:00:33+00:00 weekly 0.7 https://trial.medpath.com/news/monitoring-circulating-tumor-dna-liquid-biopsy-in-stage-iii-braf-mutant-melanoma-patients 2024-11-28T09:55:02+00:00 weekly 0.7 https://trial.medpath.com/news/first-patient-dosed-in-phase-iii-zircon-cp-trial-of-tlx250-cdx-for-kidney-cancer-imaging 2024-11-28T09:49:37+00:00 weekly 0.7 https://trial.medpath.com/news/new-indication-of-olverembatinib-included-into-china-2024-national-reimbursement-drug-list 2024-11-28T09:47:38+00:00 weekly 0.7 https://trial.medpath.com/news/stanford-medicine-study-discovers-what-s-behind-heart-cell-damage-from-chemotherapy 2024-11-28T09:32:54+00:00 weekly 0.7 https://trial.medpath.com/news/antengene-announces-xpovio-r-s-new-indication-included-in-2024-china-national 2024-11-28T09:23:50+00:00 weekly 0.7 https://trial.medpath.com/news/targeted-therapies-show-promise-in-pancreatic-cancer-treatment-but-durability-remains-a-challenge 2024-11-28T09:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/celltrion-files-european-ind-for-phase-3-trial-of-darzalex-biosimilar-bio-article-kbr 2024-11-28T08:32:18+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-kisqali-r-receives-european-commission-approval-in-a-broad-population-of-patients 2024-11-28T08:19:49+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-trial-offers-new-hope-for-cystic-fibrosis-patients-drug-target-review 2024-11-28T08:04:53+00:00 weekly 0.7 https://trial.medpath.com/news/ivig-treatment-can-lead-to-false-positive-results-in-serum-protein-electrophoresis-testing 2024-11-28T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/trump-s-healthcare-agency-nominations-signal-major-shake-up-in-us-pharma-landscape 2024-11-28T07:42:04+00:00 weekly 0.7 https://trial.medpath.com/news/cutia-therapeutics-unveils-promising-phase-iii-trial-results-markets-insider 2024-11-28T07:25:43+00:00 weekly 0.7 https://trial.medpath.com/news/astro-issues-new-guidelines-for-radiation-therapy-in-bone-metastases-treatment 2024-11-28T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/akiram-therapeutics-to-showcase-key-data-on-akir001-at-targeted-radiopharmaceuticals 2024-11-28T06:28:10+00:00 weekly 0.7 https://trial.medpath.com/news/galderma-s-phase-iii-olympia-1-trial-results-show-nemolizumab-significantly-improves-prurigo-nodularis-symptoms 2024-11-28T06:08:11+00:00 weekly 0.7 https://trial.medpath.com/news/car-t-cell-therapy-patient-resources-bristol-myers-squibb 2024-11-28T03:47:20+00:00 weekly 0.7 https://trial.medpath.com/news/phase-1b-2-study-of-bxq-350-in-metastatic-colorectal-cancer-completes-enrollment 2024-11-28T03:27:17+00:00 weekly 0.7 https://trial.medpath.com/news/phase-iii-amd-data-damage-outlook-shares-but-bla-plan-intact-bioworld 2024-11-28T02:14:33+00:00 weekly 0.7 https://trial.medpath.com/news/lexicon-completes-subject-enrolment-for-dpnp-trial-of-lx9211-clinical-trials-arena 2024-11-28T01:44:45+00:00 weekly 0.7 https://trial.medpath.com/news/pegylated-uricase-well-tolerated-demonstrates-dose-dependent-urate-lowering 2024-11-28T01:29:12+00:00 weekly 0.7 https://trial.medpath.com/news/drug-now-in-testing-has-promise-for-epileptic-seizures-national-union-bulletin-com 2024-11-28T01:22:55+00:00 weekly 0.7 https://trial.medpath.com/news/medscape-extend-launches-revolutionary-hcp-verified-programmatic-advertising-platform-for-pharma-marketers 2024-11-28T01:21:37+00:00 weekly 0.7 https://trial.medpath.com/news/predictive-tool-for-melanoma-could-guide-immunotherapy-choices 2024-11-28T00:56:14+00:00 weekly 0.7 https://trial.medpath.com/news/eisai-biogen-launch-breakthrough-alzheimer-s-drug-leqembi-in-south-korea-stock-titan 2024-11-28T00:43:07+00:00 weekly 0.7 https://trial.medpath.com/news/accelerated-access-to-novel-cancer-therapies-at-moores-cancer-center-advamed 2024-11-28T00:00:56+00:00 weekly 0.7 https://trial.medpath.com/news/igg4-related-disease-clinical-trials-2024-ema-pdma-fda 2024-11-28T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/doctors-hail-first-breakthrough-in-asthma-and-copd-treatment-in-50-years-the-guardian 2024-11-27T23:37:03+00:00 weekly 0.7 https://trial.medpath.com/news/major-australian-breakthrough-could-revolutionise-hypertension-treatment-news-hub 2024-11-27T22:59:54+00:00 weekly 0.7 https://trial.medpath.com/news/outlook-therapeutics-stock-craters-as-wet-amd-drug-fails-phase-iii-trial 2024-11-27T22:49:52+00:00 weekly 0.7 https://trial.medpath.com/news/myotonic-dystrophy-clinical-trial-pipeline-boom-as-over-20-companies-leading-pr-newswire 2024-11-27T22:36:58+00:00 weekly 0.7 https://trial.medpath.com/news/health-canada-approves-novo-nordisk-s-obesity-drug-to-reduce-risk-of-non-fatal-heart-attack 2024-11-27T21:42:15+00:00 weekly 0.7 https://trial.medpath.com/news/fda-rejects-applied-therapeutics-govorestat-for-classic-galactosemia-treatment 2024-11-27T21:18:47+00:00 weekly 0.7 https://trial.medpath.com/news/study-highlights-trimodality-bladder-preserving-therapy-as-possible-option-for-certain 2024-11-27T21:17:13+00:00 weekly 0.7 https://trial.medpath.com/news/polish-scientists-develop-breakthrough-cancer-treatment-english-section-polskie-radio 2024-11-27T20:47:46+00:00 weekly 0.7 https://trial.medpath.com/news/rutgers-cancer-institute-and-rwjbarnabas-health-to-unveil-pioneering-blood-cancer-research 2024-11-27T20:40:07+00:00 weekly 0.7 https://trial.medpath.com/news/discussions-swirl-on-the-role-of-pd-1-inhibitors-for-gastric-gej-escc-cancers-with-1 2024-11-27T20:07:01+00:00 weekly 0.7 https://trial.medpath.com/news/lin-bioscience-receives-u-s-fda-fast-track-designation-for-lbs-007 2024-11-27T20:02:36+00:00 weekly 0.7 https://trial.medpath.com/news/officials-provide-update-on-phase-3-skyscraper-01-study-docwire-news 2024-11-27T19:51:01+00:00 weekly 0.7 https://trial.medpath.com/news/winrevair-excels-at-advanced-pah-in-phase-3-trial-all-offered-treatment 2024-11-27T19:33:55+00:00 weekly 0.7 https://trial.medpath.com/news/pbc-therapy-ocaliva-gets-conditional-nod-revoked-in-europe-bioworld 2024-11-27T19:29:59+00:00 weekly 0.7 https://trial.medpath.com/news/nasal-spray-drug-could-revolutionize-alzheimer-s-treatment-the-brighter-side-of-news 2024-11-27T19:20:20+00:00 weekly 0.7 https://trial.medpath.com/news/abequolixron-docetaxel-produces-durable-responses-in-recurrent-advanced-nsclc 2024-11-27T19:07:09+00:00 weekly 0.7 https://trial.medpath.com/news/overall-survival-not-improved-with-maintenance-niraparib-in-advanced-ovarian-cancer 2024-11-27T19:01:50+00:00 weekly 0.7 https://trial.medpath.com/news/hunting-heart-attacks-cardiologist-s-whistleblower-suit-algorithm-predicts-death 2024-11-27T19:01:26+00:00 weekly 0.7 https://trial.medpath.com/news/scribe-therapeutics-verifies-in-vivo-crispr-based-cardiometabolic-therapies 2024-11-27T18:48:18+00:00 weekly 0.7 https://trial.medpath.com/news/safety-and-efficacy-of-deucravacitinib-in-moderate-to-severe-plaque-psoriasis-for-up-to-3-years 2024-11-27T18:23:27+00:00 weekly 0.7 https://trial.medpath.com/news/amgen-s-phase-2-results-were-not-bad-don-t-let-mr-market-fool-you-nasdaq-amgn 2024-11-27T18:19:01+00:00 weekly 0.7 https://trial.medpath.com/news/healthy-returns-trump-fda-pick-makary-may-be-a-relief-for-biotech-pharma-cnbc 2024-11-27T18:12:49+00:00 weekly 0.7 https://trial.medpath.com/news/widetrial-to-manage-physician-network-for-ibudilast-eap-als-news-today 2024-11-27T18:06:22+00:00 weekly 0.7 https://trial.medpath.com/news/intravenous-lidocaine-for-gut-function-recovery-in-colonic-surgery-a-randomized-clinical-trial 2024-11-27T17:23:53+00:00 weekly 0.7 https://trial.medpath.com/news/decoding-sma-progression-hfmse-analysis-spotlights-variability 2024-11-27T17:18:41+00:00 weekly 0.7 https://trial.medpath.com/news/tislelizumab-chemo-approved-by-european-commission-for-escc-gej-cancer-network 2024-11-27T17:05:03+00:00 weekly 0.7 https://trial.medpath.com/news/car-t-cells-armed-with-il-15-show-promise-in-treating-solid-cancers-bcm 2024-11-27T16:46:40+00:00 weekly 0.7 https://trial.medpath.com/news/choice-of-end-points-in-heart-failure-trials-cause-specific-or-all-cause-or-both 2024-11-27T16:26:20+00:00 weekly 0.7 https://trial.medpath.com/news/bridgebio-s-attr-cm-approval-cassava-s-alzheimer-s-failure-trump-s-cabinet-picks-more 2024-11-27T16:25:48+00:00 weekly 0.7 https://trial.medpath.com/news/locoregional-therapies-for-hepatocellular-carcinoma-a-systematic-review-and-meta-analysis 2024-11-27T16:25:46+00:00 weekly 0.7 https://trial.medpath.com/news/toxicity-and-costs-of-cancer-treatment-reduced-by-deferring-cdk4-6-inhibitor-use-nature 2024-11-27T16:21:30+00:00 weekly 0.7 https://trial.medpath.com/news/the-race-for-approval-oral-glp-1r-therapies-in-obesity-pharmaceutical-technology 2024-11-27T16:20:55+00:00 weekly 0.7 https://trial.medpath.com/news/ptc-therapeutics-als-drug-fails-to-meet-endpoints-as-trials-shut-down-yahoo-finance 2024-11-27T15:28:21+00:00 weekly 0.7 https://trial.medpath.com/news/rilzabrutinib-first-biosimilar-golimumab-among-new-eu-filings 2024-11-27T15:20:18+00:00 weekly 0.7 https://trial.medpath.com/news/lundbeck-initiates-phase-iii-study-medwatch 2024-11-27T15:13:34+00:00 weekly 0.7 https://trial.medpath.com/news/gravitas-medical-inc-announces-second-fda-clearance-for-its-entarik-system-prweb 2024-11-27T15:01:36+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-landiolol-for-treatment-of-supraventricular-tachycardia-pharmacy-times 2024-11-27T14:52:57+00:00 weekly 0.7 https://trial.medpath.com/news/the-biggest-pharma-share-moves-of-the-year-so-far-biospace 2024-11-27T14:09:49+00:00 weekly 0.7 https://trial.medpath.com/news/university-hospital-cologne-and-gustave-roussy-launch-franco-german-research-project 2024-11-27T14:09:48+00:00 weekly 0.7 https://trial.medpath.com/news/nutriband-secures-hong-kong-patent-for-aversa-abuse-deterrent-fentanyl-patch-technology 2024-11-27T13:56:49+00:00 weekly 0.7 https://trial.medpath.com/news/alk-s-pivotal-phase-3-trial-in-children-published-in-reputable-scientific-journal-biospace 2024-11-27T13:37:50+00:00 weekly 0.7 https://trial.medpath.com/news/updated-mdna11-monotherapy-and-combination-clinical-data-from-the-ongoing-phase-1-2 2024-11-27T13:37:48+00:00 weekly 0.7 https://trial.medpath.com/news/aulos-bioscience-doses-first-patient-in-phase-2-cohort-evaluating-the-combination-of-biospace 2024-11-27T13:37:47+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-in-early-cancer-screening-go-to-the-dogs-mediapost 2024-11-27T13:32:55+00:00 weekly 0.7 https://trial.medpath.com/news/nccn-updates-2024-2025-multiple-myeloma-guidelines-quadruplet-therapy-and-immunotherapy-take-center-stage 2024-11-27T12:01:39+00:00 weekly 0.7 https://trial.medpath.com/news/what-you-missed-at-aao-2024-abbv-rgx-314-for-wet-amd-modern-retina 2024-11-27T11:58:56+00:00 weekly 0.7 https://trial.medpath.com/news/outlook-therapeutics-r-announces-preliminary-topline-results-of-norse-eight-clinical-trial 2024-11-27T11:57:36+00:00 weekly 0.7 https://trial.medpath.com/news/china-medical-system-gets-green-light-for-obesity-drug-trials-tipranks-com 2024-11-27T11:56:55+00:00 weekly 0.7 https://trial.medpath.com/news/putting-the-uk-back-on-the-map-for-clinical-trials-nweh-partners-with-cprd 2024-11-27T11:36:10+00:00 weekly 0.7 https://trial.medpath.com/news/biostock-elicera-s-ceo-elc-100-stands-apart-from-all-other-standard-treatments 2024-11-27T11:27:03+00:00 weekly 0.7 https://trial.medpath.com/news/for-agitation-in-alzheimer-disease-a-novel-oral-nmda-receptor-antagonist-could-be-the 2024-11-27T11:11:33+00:00 weekly 0.7 https://trial.medpath.com/news/nerve-stimulation-device-might-ease-long-covid-symptoms 2024-11-27T11:11:03+00:00 weekly 0.7 https://trial.medpath.com/news/beigene-s-tevimbra-wins-eu-approval-after-breakthrough-cancer-survival-data 2024-11-27T11:10:54+00:00 weekly 0.7 https://trial.medpath.com/news/although-not-approved-by-the-ema-bavaria-is-considering-buying-the-russian-vaccine 2024-11-27T11:00:36+00:00 weekly 0.7 https://trial.medpath.com/news/the-role-of-cabazitaxel-in-patients-with-castration-resistant-and-osseous-metastases-urotoday 2024-11-27T10:35:54+00:00 weekly 0.7 https://trial.medpath.com/news/axsome-therapeutics-eyes-approval-after-phase-iii-narcolepsy-win-clinical-trials-arena 2024-11-27T09:54:23+00:00 weekly 0.7 https://trial.medpath.com/news/emd-completes-raise-chairman-invests-1m-next-investors 2024-11-27T09:46:29+00:00 weekly 0.7 https://trial.medpath.com/news/peptide-cancer-drug-market-research-2024-2030-230-drugs-in-clinical-trials-yahoo-finance 2024-11-27T09:24:23+00:00 weekly 0.7 https://trial.medpath.com/news/maxilus-study-looks-to-further-elucidate-the-role-of-luspatercept-in-mds-onclive 2024-11-27T09:18:05+00:00 weekly 0.7 https://trial.medpath.com/news/lundbeck-initiates-a-phase-iii-trial-with-amlenetug-for-the-treatment-of-multiple-system-atrophy 2024-11-27T08:53:19+00:00 weekly 0.7 https://trial.medpath.com/news/positive-phase-2-interim-results-from-bexmab-trial-faron-pharmaceuticals-oy 2024-11-27T08:53:19+00:00 weekly 0.7 https://trial.medpath.com/news/next-biomedical-wins-approval-for-gi-bleeding-prevention-powder-device-ict-article 2024-11-27T08:12:49+00:00 weekly 0.7 https://trial.medpath.com/news/precision-medicine-in-prostate-cancer-faces-implementation-challenges-despite-progress 2024-11-27T08:02:48+00:00 weekly 0.7 https://trial.medpath.com/news/early-stage-trial-finds-stem-cell-therapy-for-retinitis-pigmentosa-is-safe-uc-davis-health 2024-11-27T07:48:55+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-evidence-trials-surge-in-2024-china-leads-global-research-efforts 2024-11-27T07:29:01+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-s-fully-liquid-menveo-meningococcal-vaccine-approved-by-european-commission 2024-11-27T07:08:40+00:00 weekly 0.7 https://trial.medpath.com/news/fluoguide-a-s-publishes-interim-report-for-the-period-january-september-2024 2024-11-27T06:20:00+00:00 weekly 0.7 https://trial.medpath.com/news/synact-pharma-receives-eu-trial-approval-for-the-phase-2b-advance-study-with 2024-11-27T06:04:59+00:00 weekly 0.7 https://trial.medpath.com/news/arrowhead-pharmaceuticals-fda-acceptance-of-plozasiran-nda-marks-milestone-in-rnai-therapeutics 2024-11-27T04:22:55+00:00 weekly 0.7 https://trial.medpath.com/news/first-patient-dosed-in-ridge-1-trial-for-tenaya-s-arv-cardiomyopathy-gene-therapy-tn-401 2024-11-27T04:04:06+00:00 weekly 0.7 https://trial.medpath.com/news/pyc-therapeutics-advances-kidney-disease-drug-trials-markets-insider 2024-11-27T03:45:34+00:00 weekly 0.7 https://trial.medpath.com/news/amgen-announces-robust-weight-loss-with-maritide-in-people-living-with 2024-11-27T03:45:06+00:00 weekly 0.7 https://trial.medpath.com/news/phd-student-s-radiopharmaceutical-to-play-key-role-in-clinical-trial-for-lung-cancer-treatment 2024-11-27T03:29:00+00:00 weekly 0.7 https://trial.medpath.com/news/vectus-biosystems-advances-drug-trials-and-commercialization-tipranks-com 2024-11-27T02:54:11+00:00 weekly 0.7 https://trial.medpath.com/news/newer-epilepsy-medications-used-during-pregnancy-do-not-affect-neurological-development-in-children 2024-11-27T02:11:14+00:00 weekly 0.7 https://trial.medpath.com/news/news-roundup-oak-street-s-pykosz-departs-cvs-musk-s-neuralink-gains-canadian-clinical 2024-11-27T01:03:59+00:00 weekly 0.7 https://trial.medpath.com/news/novel-hypofractionated-proton-beam-therapy-for-older-patients-with-newly-diagnosed 2024-11-27T00:55:15+00:00 weekly 0.7 https://trial.medpath.com/news/generative-ai-revolutionizes-drug-safety-monitoring-with-real-time-analysis-capabilities 2024-11-27T00:29:46+00:00 weekly 0.7 https://trial.medpath.com/news/novel-mettl3-inhibitor-elicits-clinical-activity-across-tumor-types-targeted-oncology 2024-11-27T00:03:44+00:00 weekly 0.7 https://trial.medpath.com/news/viromed-medical-ag-advances-cold-plasma-technology-as-digital-antibiotic-for-ventilator-associated-pneumonia-prevention 2024-11-27T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/amgen-s-phase-ii-maritide-data-lack-clarity-market-hoped-for-citeline 2024-11-26T23:58:30+00:00 weekly 0.7 https://trial.medpath.com/news/an-rna-biotech-draws-the-blueprint-for-a-late-stage-dravet-syndrome-trial-and-beyond 2024-11-26T23:24:56+00:00 weekly 0.7 https://trial.medpath.com/news/tc-s-lori-quinn-tapped-for-huntington-s-disease-study-supported-by-the-fda 2024-11-26T22:35:06+00:00 weekly 0.7 https://trial.medpath.com/news/healthcare-september-and-october-2024-regulatory-updates 2024-11-26T21:55:01+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimer-s-trials-fail-blood-test-predicts-tau-neuroscience-moves-to-bluesky 2024-11-26T20:59:54+00:00 weekly 0.7 https://trial.medpath.com/news/diabetes-drug-appears-to-fight-lung-cancer-but-only-in-overweight-or-obese-patients 2024-11-26T20:07:25+00:00 weekly 0.7 https://trial.medpath.com/news/multiomics-approaches-disclose-very-early-molecular-and-cellular-switches-during-insect-nature 2024-11-26T19:31:24+00:00 weekly 0.7 https://trial.medpath.com/news/asgct-s-q3-2024-landscape-report-cgtlive-r 2024-11-26T18:17:25+00:00 weekly 0.7 https://trial.medpath.com/news/people-with-hiv-can-now-receive-livers-kidneys-from-hiv-positive-donors 2024-11-26T18:11:10+00:00 weekly 0.7 https://trial.medpath.com/news/failure-of-astrazeneca-s-azd4041-a-blow-for-non-opioid-oud-treatments 2024-11-26T18:08:57+00:00 weekly 0.7 https://trial.medpath.com/news/assessing-omaveloxolone-s-positive-long-term-safety-profile-david-lynch-md-phd 2024-11-26T17:50:55+00:00 weekly 0.7 https://trial.medpath.com/news/spatially-organized-tumor-stroma-boundary-determines-the-efficacy-of-immunotherapy-in 2024-11-26T17:33:21+00:00 weekly 0.7 https://trial.medpath.com/news/an-early-switch-in-first-line-therapy-improves-outcomes-of-advanced-stage-g-gejc-nature 2024-11-26T17:08:07+00:00 weekly 0.7 https://trial.medpath.com/news/tamoxifen-response-rate-influenced-by-gut-microbiome-inside-precision-medicine 2024-11-26T16:52:35+00:00 weekly 0.7 https://trial.medpath.com/news/hit-and-miss-for-cdk4-6-inhibitor-in-recurrent-brain-cancer-medpage-today 2024-11-26T16:51:38+00:00 weekly 0.7 https://trial.medpath.com/news/geographic-disparities-in-gynecologic-oncology-clinical-trial-availability-in-the-us-jama-network 2024-11-26T16:51:17+00:00 weekly 0.7 https://trial.medpath.com/news/valneva-submits-label-extension-application-for-its-chikungunya-vaccine-ixchiq-r-to-the-u-s-fda 2024-11-26T16:45:12+00:00 weekly 0.7 https://trial.medpath.com/news/bagegni-receives-national-cancer-institute-award-washu-medicine 2024-11-26T16:38:35+00:00 weekly 0.7 https://trial.medpath.com/news/safilens-receives-fda-approval-optician-online 2024-11-26T16:38:12+00:00 weekly 0.7 https://trial.medpath.com/news/nexus-pharmaceuticals-receives-fda-approval-for-methylene-blue-injection-usp 2024-11-26T16:16:46+00:00 weekly 0.7 https://trial.medpath.com/news/gene-signature-identified-for-high-risk-form-acute-lymphoblastic-leukemia 2024-11-26T15:55:00+00:00 weekly 0.7 https://trial.medpath.com/news/trials-and-tribulations-of-cell-therapy-for-heart-failure-an-update-on-ongoing-trials-news 2024-11-26T15:48:33+00:00 weekly 0.7 https://trial.medpath.com/news/crispr-clinical-trial-targets-sickle-cell-at-its-genetic-roots-synbiobeta 2024-11-26T15:44:41+00:00 weekly 0.7 https://trial.medpath.com/news/pop-bio-awarded-2-84m-phase-ii-sbir-for-seasonal-influenza-vaccine-development 2024-11-26T15:43:04+00:00 weekly 0.7 https://trial.medpath.com/news/your-skin-color-may-affect-how-well-a-medication-works-for-you-but-the-research-is-way-behind 2024-11-26T15:34:49+00:00 weekly 0.7 https://trial.medpath.com/news/onvansertib-combo-shows-significant-efficacy-in-kras-colorectal-cancer 2024-11-26T15:04:43+00:00 weekly 0.7 https://trial.medpath.com/news/initial-impressions-of-the-cepheus-clinical-trial-in-transplant-not-preferred-ndmm 2024-11-26T14:56:01+00:00 weekly 0.7 https://trial.medpath.com/news/vir-biotechnology-to-host-virtual-investor-event-on-pro-xtentm-masked-t-cell-engager-programs 2024-11-26T14:42:34+00:00 weekly 0.7 https://trial.medpath.com/news/soleno-s-pws-drug-dccr-gets-3-month-fda-review-extension-no-safety-concerns-cited 2024-11-26T13:39:49+00:00 weekly 0.7 https://trial.medpath.com/news/dmd-gene-therapy-gnt0004-set-to-enter-phase-3-trial-in-europe-us 2024-11-26T13:25:56+00:00 weekly 0.7 https://trial.medpath.com/news/ensysce-biosciences-launches-key-trial-for-breakthrough-opioid-drug-backed-by-14m-nida-grant 2024-11-26T13:20:29+00:00 weekly 0.7 https://trial.medpath.com/news/scholar-rock-s-stock-target-increased-following-sma-study-results 2024-11-26T13:12:56+00:00 weekly 0.7 https://trial.medpath.com/news/maat-pharma-eyes-phase-ii-after-early-success-in-als-microbiome-trial-yahoo-finance 2024-11-26T13:06:54+00:00 weekly 0.7 https://trial.medpath.com/news/otsuka-submits-new-drug-application-in-japan-for-bempedoic-globenewswire 2024-11-26T13:06:29+00:00 weekly 0.7 https://trial.medpath.com/news/medigene-ag-announces-refocus-of-corporate-strategy-and-organizational-realignment 2024-11-26T13:06:25+00:00 weekly 0.7 https://trial.medpath.com/news/briacell-s-breast-cancer-therapy-shows-13-4-month-survival-rate-in-phase-2-trial 2024-11-26T12:59:54+00:00 weekly 0.7 https://trial.medpath.com/news/study-unlocks-the-secrets-of-beta-cell-regeneration-news-medical 2024-11-26T12:56:29+00:00 weekly 0.7 https://trial.medpath.com/news/severe-toxicities-in-amazonian-populations-and-the-role-of-precision-medicine-in-acute-nature 2024-11-26T12:38:09+00:00 weekly 0.7 https://trial.medpath.com/news/alector-s-abbvie-partnered-alzheimer-s-program-fails-phase-ii-triggering-a-17-layoff 2024-11-26T12:30:28+00:00 weekly 0.7 https://trial.medpath.com/news/brenig-therapeutics-announces-the-initiation-of-first-in-human-clinical-trial-of-bt-267-a 2024-11-26T12:23:24+00:00 weekly 0.7 https://trial.medpath.com/news/arrowhead-pharma-lands-825m-mega-deal-with-sarepta-up-to-10b-in-milestones-stock-titan 2024-11-26T12:17:05+00:00 weekly 0.7 https://trial.medpath.com/news/crohn-s-disease-clinical-trials-2024-ema-pdma-fda-approvals-openpr-com 2024-11-26T12:10:17+00:00 weekly 0.7 https://trial.medpath.com/news/amgen-to-host-webcast-to-discuss-maritide-phase-2-results-and 2024-11-26T12:08:50+00:00 weekly 0.7 https://trial.medpath.com/news/mvitro-s-needle-free-blood-sampling-device-ortiv-wins-fda-approval-kbr 2024-11-26T11:56:26+00:00 weekly 0.7 https://trial.medpath.com/news/greenwich-lifesciences-partners-with-gim-in-italy-stock-titan 2024-11-26T11:20:37+00:00 weekly 0.7 https://trial.medpath.com/news/an-assortment-of-journal-abstracts-to-enhance-oncology-care 2024-11-26T11:18:05+00:00 weekly 0.7 https://trial.medpath.com/news/ziftomenib-shows-promise-in-treatment-resistant-aml-oncology-times 2024-11-26T11:18:04+00:00 weekly 0.7 https://trial.medpath.com/news/delta-fly-pharma-inc-progress-update-of-the-phase-iii-clinical-trial-of-dfp-14323-news 2024-11-26T11:16:57+00:00 weekly 0.7 https://trial.medpath.com/news/study-examines-efficiency-of-physiotherapy-in-treating-preventing-uncomplicated-acquired-myopia 2024-11-26T11:14:20+00:00 weekly 0.7 https://trial.medpath.com/news/there-s-a-best-option-for-patients-with-head-and-neck-cancer-who-can-t-take-cisplatin 2024-11-26T11:11:40+00:00 weekly 0.7 https://trial.medpath.com/news/application-of-machine-learning-algorithms-to-identify-serological-predictors-of-covid-19 2024-11-26T10:59:54+00:00 weekly 0.7 https://trial.medpath.com/news/olema-oncology-to-present-new-data-combining-palazestrant-globenewswire 2024-11-26T10:31:59+00:00 weekly 0.7 https://trial.medpath.com/news/imcheck-to-present-encouraging-interim-results-in-aml-globenewswire 2024-11-26T10:05:56+00:00 weekly 0.7 https://trial.medpath.com/news/shilpa-medicare-gets-nod-to-conduct-phase-iii-clinical-trials-for-recombinant-human-albumin-20 2024-11-26T08:59:01+00:00 weekly 0.7 https://trial.medpath.com/news/celldex-therapeutics-swot-analysis-barzolvolimab-stock-shows-promise-in-urticaria-treatment 2024-11-26T08:48:40+00:00 weekly 0.7 https://trial.medpath.com/news/consuming-chinese-medicinal-tea-eases-sjogren-s-symptom-severity 2024-11-26T08:25:26+00:00 weekly 0.7 https://trial.medpath.com/news/anocca-announces-submission-of-clinical-trial-application-for-multi-asset-trial-vidar-1-in 2024-11-26T08:17:00+00:00 weekly 0.7 https://trial.medpath.com/news/hemogenyx-pharmaceuticals-explains-share-consolidation-greenlight-for-clinical-trial 2024-11-26T07:33:26+00:00 weekly 0.7 https://trial.medpath.com/news/roche-reports-update-on-phase-iii-skyscraper-01-study-results-globenewswire 2024-11-26T06:01:50+00:00 weekly 0.7 https://trial.medpath.com/news/va-expands-cancer-care-access-through-innovative-programs-and-telehealth-services 2024-11-26T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/gc-biopharma-and-novel-pharma-first-patient-dosed-in-global-phase-i-clinical-trial-for 2024-11-26T05:50:38+00:00 weekly 0.7 https://trial.medpath.com/news/emerging-data-on-oral-serds-targeted-oncology 2024-11-26T05:39:07+00:00 weekly 0.7 https://trial.medpath.com/news/slope-and-labconnect-launch-revolutionary-api-integration-to-transform-clinical-trial-sample-management 2024-11-26T04:42:00+00:00 weekly 0.7 https://trial.medpath.com/news/eu-postpones-decision-on-biontech-and-pfizer-vaccine-approval-telegrafi 2024-11-26T03:01:51+00:00 weekly 0.7 https://trial.medpath.com/news/deep-brain-stimulation-of-hippocampus-in-treatment-resistant-schizophrenia-dbs-hits 2024-11-26T02:40:17+00:00 weekly 0.7 https://trial.medpath.com/news/long-term-data-solidify-the-role-of-zanubrutinib-in-r-r-cll-with-alexey-danilov-md-phd 2024-11-26T01:03:36+00:00 weekly 0.7 https://trial.medpath.com/news/pmcpa-sanctions-moderna-for-code-violations-in-covid-19-vaccine-promotion-and-trial-recruitment 2024-11-26T01:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-outcome-assessments-and-biomarkers-in-charcot-marie-tooth-disease-pubmed 2024-11-25T23:52:16+00:00 weekly 0.7 https://trial.medpath.com/news/alector-therapeutics-novel-alzheimer-s-strategy-fails-in-phase-2-trial-stat-news 2024-11-25T22:59:44+00:00 weekly 0.7 https://trial.medpath.com/news/empyrean-therapeutics-acquires-tlr-2-antagonist-molecule-from-eos-therapies-to 2024-11-25T22:39:27+00:00 weekly 0.7 https://trial.medpath.com/news/many-people-remain-excluded-from-glp-1-clinical-trials-for-weight-loss-healio 2024-11-25T22:02:55+00:00 weekly 0.7 https://trial.medpath.com/news/zimmer-biomet-receives-fda-approval-for-oxford-r-cementless-partial-knee-only-pr-newswire 2024-11-25T21:58:48+00:00 weekly 0.7 https://trial.medpath.com/news/emerald-subgroup-analysis-elacestrant-in-endocrine-sensitive-disease-targeted-oncology 2024-11-25T21:54:19+00:00 weekly 0.7 https://trial.medpath.com/news/a-universal-gene-therapy-for-diamond-blackfan-anemia-is-poised-for-clinical-trials 2024-11-25T21:50:21+00:00 weekly 0.7 https://trial.medpath.com/news/efficacy-and-safety-of-human-umbilical-cord-derived-mesenchymal-stem-cells-versus 2024-11-25T20:40:11+00:00 weekly 0.7 https://trial.medpath.com/news/xenon-pharmaceuticals-swot-analysis-stock-poised-for-breakthrough-in-epilepsy 2024-11-25T18:39:28+00:00 weekly 0.7 https://trial.medpath.com/news/modified-folfoxiri-plus-cetuximab-versus-bevacizumab-in-ras-wild-type-metastatic-nature 2024-11-25T17:58:23+00:00 weekly 0.7 https://trial.medpath.com/news/mereo-biopharma-s-swot-analysis-rare-disease-stock-poised-for-growth-investing-com 2024-11-25T17:54:24+00:00 weekly 0.7 https://trial.medpath.com/news/biohaven-shares-retain-outperform-rating-as-baird-highlights-optimism-for-obesity-phase-2-trial 2024-11-25T17:53:46+00:00 weekly 0.7 https://trial.medpath.com/news/blue-lake-and-cyanvac-report-positive-phase-2a-data-for-intranasal-covid-19-vaccine-candidate 2024-11-25T17:33:40+00:00 weekly 0.7 https://trial.medpath.com/news/briohealth-solutions-begins-patient-enrollment-in-innovate-trial-of-briovad-r-system-for 2024-11-25T17:33:34+00:00 weekly 0.7 https://trial.medpath.com/news/rti-surgical-announces-first-patient-enrolled-in-investigational-device-exemption-ide-for 2024-11-25T17:33:33+00:00 weekly 0.7 https://trial.medpath.com/news/msk-care-for-a-young-woman-living-with-stage-4-egfr-lung-cancer 2024-11-25T17:27:56+00:00 weekly 0.7 https://trial.medpath.com/news/updated-phase-iii-mirasol-trial-results-mirvetuximab-soravtansine-vs-chemotherapy-in 2024-11-25T17:14:11+00:00 weekly 0.7 https://trial.medpath.com/news/early-promise-for-pi3k-inhibitor-in-brain-metastases-medpage-today 2024-11-25T17:11:35+00:00 weekly 0.7 https://trial.medpath.com/news/patient-reported-quality-of-life-and-adherence-outcomes-after-integrating-exclusive-liquid 2024-11-25T17:09:32+00:00 weekly 0.7 https://trial.medpath.com/news/sel-212-advances-refractory-gout-outcomes-with-prolonged-treatment-hcplive 2024-11-25T17:04:37+00:00 weekly 0.7 https://trial.medpath.com/news/new-data-could-help-merck-expand-use-of-cardiovascular-drug-biopharma-dive 2024-11-25T17:00:14+00:00 weekly 0.7 https://trial.medpath.com/news/outcomes-in-randomized-clinical-trials-testing-changes-in-daily-water-intake 2024-11-25T16:51:24+00:00 weekly 0.7 https://trial.medpath.com/news/biotech-breakthrough-a-new-hope-for-cancer-treatment-shocking-ipo-plans-revealed 2024-11-25T16:37:00+00:00 weekly 0.7 https://trial.medpath.com/news/igc-pharma-announces-additional-phase-2-interim-results-highlighting-cognitive-benefits 2024-11-25T16:11:16+00:00 weekly 0.7 https://trial.medpath.com/news/fda-advised-to-update-labels-on-glp-1-weight-loss-drugs 2024-11-25T16:02:03+00:00 weekly 0.7 https://trial.medpath.com/news/biohaven-drug-misses-in-phase-iii-for-sma-will-be-tested-in-obesity-biospace 2024-11-25T15:53:55+00:00 weekly 0.7 https://trial.medpath.com/news/advances-in-small-cell-lung-cancer-classification 2024-11-25T15:22:50+00:00 weekly 0.7 https://trial.medpath.com/news/incyte-to-spotlight-new-data-including-a-late-breaking-oral-presentation-for-tafasitamab-in 2024-11-25T15:22:05+00:00 weekly 0.7 https://trial.medpath.com/news/managinglife-launches-innovative-psychology-intervention-for-post-surgical-pain-and-opioid-use 2024-11-25T15:10:29+00:00 weekly 0.7 https://trial.medpath.com/news/ec-ordered-to-pay-cost-of-pharmamar-vs-ema-case-european-biotechnology-magazine 2024-11-25T15:03:01+00:00 weekly 0.7 https://trial.medpath.com/news/bridgebio-shares-retain-buy-rating-as-h-c-wainwright-highlights-attruby-fda-approval 2024-11-25T14:57:55+00:00 weekly 0.7 https://trial.medpath.com/news/cassava-sciences-controversial-alzheimer-s-drug-fails-to-hit-primary-goal-in-pivotal-study 2024-11-25T14:43:29+00:00 weekly 0.7 https://trial.medpath.com/news/nih-developed-ai-algorithm-matches-potential-volunteers-to-clinical-trials-hep 2024-11-25T14:41:47+00:00 weekly 0.7 https://trial.medpath.com/news/weekly-report-phase-3-data-for-jnj2113-expert-discussions-and-more 2024-11-25T14:35:44+00:00 weekly 0.7 https://trial.medpath.com/news/readout-newsletter-trump-s-cdc-fda-nominees-merck-alnylam-stat-news 2024-11-25T14:32:20+00:00 weekly 0.7 https://trial.medpath.com/news/bioadaptives-inc-announces-institutional-review-board-approval-of-a-human-clinical-trial 2024-11-25T14:30:58+00:00 weekly 0.7 https://trial.medpath.com/news/bioadaptives-launches-clinical-trial-for-weight-management-alternative-to-glp-1-drugs 2024-11-25T14:27:54+00:00 weekly 0.7 https://trial.medpath.com/news/cassava-stock-plunges-as-alzheimer-s-drug-fails-late-stage-study-investopedia 2024-11-25T14:23:48+00:00 weekly 0.7 https://trial.medpath.com/news/food-allergy-longbio-s-lp-003-achieves-its-fourth-ind-approval-morningstar 2024-11-25T14:21:13+00:00 weekly 0.7 https://trial.medpath.com/news/bioadaptives-inc-announces-institutional-review-board 2024-11-25T14:20:47+00:00 weekly 0.7 https://trial.medpath.com/news/neurotech-innovator-uneeg-medical-receives-fda-breakthrough-device-designation 2024-11-25T14:17:58+00:00 weekly 0.7 https://trial.medpath.com/news/new-malaria-vaccine-shows-high-protection-in-clinical-trial-medical-xpress 2024-11-25T14:08:50+00:00 weekly 0.7 https://trial.medpath.com/news/cns-pharma-s-berubicin-shows-higher-patient-retention-in-pivotal-gbm-trial-cnsp-stock-news 2024-11-25T14:05:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-study-adds-to-concerns-that-asthma-drug-can-harm-mental-health 2024-11-25T13:57:20+00:00 weekly 0.7 https://trial.medpath.com/news/mjff-awards-grant-to-study-skin-test-that-detects-alpha-synuclein-in-parkinson-s 2024-11-25T13:55:18+00:00 weekly 0.7 https://trial.medpath.com/news/brain-shrinkage-in-alzheimer-s-drugs-shows-effectiveness-mirage-news 2024-11-25T13:51:00+00:00 weekly 0.7 https://trial.medpath.com/news/seven-top-pharma-companies-adopt-phasev-s-machine-learning-technology-for-drug 2024-11-25T13:49:06+00:00 weekly 0.7 https://trial.medpath.com/news/south-korean-researchers-develop-clinical-laboratory-test-that-diagnoses-sepsis-faster 2024-11-25T13:36:11+00:00 weekly 0.7 https://trial.medpath.com/news/dr-schiff-on-pfs-and-os-data-with-temozolomide-plus-radiation-in-grade-ii-glioma 2024-11-25T13:34:47+00:00 weekly 0.7 https://trial.medpath.com/news/roche-receives-fda-approval-for-first-companion-diagnostic-to-identify-patients-with-biliary 2024-11-25T13:33:48+00:00 weekly 0.7 https://trial.medpath.com/news/bridgebio-gets-fda-nod-for-attruby-to-treat-attr-cm-patients 2024-11-25T13:22:40+00:00 weekly 0.7 https://trial.medpath.com/news/citius-pharmaceuticals-reports-productive-fda-type-c-meeting-to-discuss-phase-3-mino 2024-11-25T13:22:21+00:00 weekly 0.7 https://trial.medpath.com/news/nrx-pharmaceuticals-nasdaq-nrxp-announces-publication-of-paper-entitled-quality 2024-11-25T13:21:28+00:00 weekly 0.7 https://trial.medpath.com/news/citius-pharma-progresses-with-fda-on-mino-lok-approval-investing-com 2024-11-25T13:16:38+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-eyes-up-combo-approval-for-previously-withdrawn-myeloma-drug-yahoo-finance 2024-11-25T13:11:08+00:00 weekly 0.7 https://trial.medpath.com/news/citius-pharmaceuticals-reports-productive-fda-type-c-meeting-to-discuss-phase-3-mino 2024-11-25T13:10:58+00:00 weekly 0.7 https://trial.medpath.com/news/citius-pharma-advances-mino-lok-after-successful-fda-meeting-phase-3-trial-results 2024-11-25T13:09:51+00:00 weekly 0.7 https://trial.medpath.com/news/nrx-pharma-achieves-94-5-rating-accuracy-breakthrough-in-depression-trial-method 2024-11-25T13:09:46+00:00 weekly 0.7 https://trial.medpath.com/news/long-covid-patients-push-to-see-federal-research-refocused-on-treatments-npr 2024-11-25T13:09:16+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-orphan-drug-status-to-rag-21-for-treating-fus-als-als-news-today 2024-11-25T13:09:08+00:00 weekly 0.7 https://trial.medpath.com/news/tislelizumab-pushes-hcc-field-forward-with-2024-nccn-guideline-category-1-recommendation 2024-11-25T13:04:45+00:00 weekly 0.7 https://trial.medpath.com/news/bridgebio-s-attruby-to-treat-heart-condition-attr-cm-receives-fda-approval 2024-11-25T13:02:41+00:00 weekly 0.7 https://trial.medpath.com/news/breakthroughs-and-setbacks-in-the-pharmaceutical-industry-health-devdiscourse 2024-11-25T13:01:34+00:00 weekly 0.7 https://trial.medpath.com/news/merck-reports-positive-topline-results-from-the-phase-3-zenith-study-evaluating 2024-11-25T12:59:28+00:00 weekly 0.7 https://trial.medpath.com/news/world-s-1st-ai-made-lung-disease-drug-gets-phase-2-trial-in-us-china 2024-11-25T12:55:19+00:00 weekly 0.7 https://trial.medpath.com/news/iicon-supports-new-phase-ii-trial-of-novel-pneumococcal-vaccine 2024-11-25T12:53:02+00:00 weekly 0.7 https://trial.medpath.com/news/cassava-sciences-topline-phase-3-data-did-not-meet-co-primary-endpoints-stock-titan 2024-11-25T12:48:38+00:00 weekly 0.7 https://trial.medpath.com/news/palatin-announces-completion-of-patient-enrollment-in-phase-2-study-of-orally-markets-data 2024-11-25T12:33:38+00:00 weekly 0.7 https://trial.medpath.com/news/cassava-sciences-topline-phase-3-data-did-not-meet-co-primary-endpoints 2024-11-25T12:32:51+00:00 weekly 0.7 https://trial.medpath.com/news/anavex-s-alzheimer-s-drug-trial-results-accepted-for-peer-review-publication-avxl-stock-news 2024-11-25T12:32:48+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-and-protagonist-share-promising-phase-3-results-for-icotrokinra-in-plaque-psoriasis 2024-11-25T12:24:36+00:00 weekly 0.7 https://trial.medpath.com/news/merck-reports-positive-topline-results-from-the-phase-3-zenith-study-evaluating 2024-11-25T12:24:09+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-bridgebio-s-attruby-to-treat-rare-heart-disease-attr-cm-pmlive 2024-11-25T12:23:54+00:00 weekly 0.7 https://trial.medpath.com/news/msd-s-welireg-approved-by-nmpa-to-treat-vhl-disease-associated-tumours-yahoo 2024-11-25T12:22:11+00:00 weekly 0.7 https://trial.medpath.com/news/orbus-s-combo-misses-primary-endpoint-in-phase-iii-brain-cancer-trial 2024-11-25T12:20:02+00:00 weekly 0.7 https://trial.medpath.com/news/edwards-lifesciences-announces-positive-results-in-one-year-tavi-trial 2024-11-25T12:20:01+00:00 weekly 0.7 https://trial.medpath.com/news/truqap-r-capivasertib-combination-in-pten-deficient-metastatic-hormone-astrazeneca-us 2024-11-25T12:18:13+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-highlights-new-96-week-results-from-phase-iii-scemblix-r-asc4first-trial-at-ash 2024-11-25T12:17:12+00:00 weekly 0.7 https://trial.medpath.com/news/exploring-car-t-for-autoimmune-disease-cgtlive-r 2024-11-25T12:17:01+00:00 weekly 0.7 https://trial.medpath.com/news/clearside-biomedical-showcases-breakthrough-scs-technology-after-10000-successful-injections 2024-11-25T12:15:52+00:00 weekly 0.7 https://trial.medpath.com/news/lifesignals-receives-fda-510-k-approval-for-ubiqvuetm-2a-multiparameter-system 2024-11-25T12:14:37+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-stemcyte-s-cord-blood-stem-cell-therapy-bla 2024-11-25T12:13:05+00:00 weekly 0.7 https://trial.medpath.com/news/hanall-biopharma-daewoong-pharmaceutical-and-nurron-pharmaceuticals-pr-newswire 2024-11-25T12:12:30+00:00 weekly 0.7 https://trial.medpath.com/news/alnylam-s-vutrisiran-fda-review-set-for-attr-cm-treatment-expansion-alny-stock-news 2024-11-25T12:12:20+00:00 weekly 0.7 https://trial.medpath.com/news/truqap-trial-shows-breakthrough-in-pten-deficient-prostate-cancer-treatment-azn-stock-news 2024-11-25T12:12:08+00:00 weekly 0.7 https://trial.medpath.com/news/alnylam-announces-u-s-food-and-drug-administration-acceptance-of-supplemental-new 2024-11-25T12:11:50+00:00 weekly 0.7 https://trial.medpath.com/news/shorla-oncology-announces-fda-approval-of-imkeldi-imatinib-oral-solution-an-morningstar 2024-11-25T12:11:49+00:00 weekly 0.7 https://trial.medpath.com/news/kanglin-biotechnology-announces-20-million-series-a-globenewswire 2024-11-25T12:11:45+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-eyes-up-combo-approval-for-previously-withdrawn-myeloma-drug 2024-11-25T12:11:14+00:00 weekly 0.7 https://trial.medpath.com/news/china-s-nmpa-approves-msd-s-welireg-for-vhl-treatment-pharmaceutical-technology 2024-11-25T12:11:14+00:00 weekly 0.7 https://trial.medpath.com/news/clearside-biomedical-extends-global-footprint-with-numerous-globenewswire 2024-11-25T12:08:16+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-510-k-clearance-to-philips-rocc-capabilities-yahoo-finance 2024-11-25T12:07:58+00:00 weekly 0.7 https://trial.medpath.com/news/merck-s-winrevair-shows-promise-in-pah-phase-3-trial-investing-com 2024-11-25T12:04:20+00:00 weekly 0.7 https://trial.medpath.com/news/merck-announces-pivotal-phase-3-zenith-trial-evaluating-winrevairtm-sotatercept-csrk 2024-11-25T12:02:16+00:00 weekly 0.7 https://trial.medpath.com/news/merck-announces-pivotal-phase-3-zenith-trial-evaluating-winrevairtm-sotatercept-csrk 2024-11-25T11:57:00+00:00 weekly 0.7 https://trial.medpath.com/news/advantage-therapeutics-launches-klothea-bio-to-develop-klotho-based-anti-aging-therapies 2024-11-25T11:56:00+00:00 weekly 0.7 https://trial.medpath.com/news/merck-s-winrevair-shows-breakthrough-results-in-phase-3-pah-trial-study-halted-early 2024-11-25T11:55:40+00:00 weekly 0.7 https://trial.medpath.com/news/eton-pharmaceuticals-announces-acquisition-of-u-s-rights-to-amglidia-glyburide-oral-suspension 2024-11-25T11:51:43+00:00 weekly 0.7 https://trial.medpath.com/news/merck-announces-pivotal-phase-3-zenith-trial-evaluating-winrevairtm-sotatercept-csrk 2024-11-25T11:50:01+00:00 weekly 0.7 https://trial.medpath.com/news/study-points-to-a-strategy-for-inhibiting-hyper-progression-of-melanoma-news-medical 2024-11-25T11:44:44+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-efficacy-and-safety-of-the-superpulse-thulium-fiber-laser-and-holmium-laser-for-trials 2024-11-25T11:35:09+00:00 weekly 0.7 https://trial.medpath.com/news/study-finds-bone-density-loss-associated-with-levothyroxine-news-medical 2024-11-25T11:24:45+00:00 weekly 0.7 https://trial.medpath.com/news/scg-s-hbv-t-cell-therapy-shows-promise-in-phase-i-trial 2024-11-25T11:17:28+00:00 weekly 0.7 https://trial.medpath.com/news/us-fda-grants-approval-for-zanidatamab-ziihera-bispecific-antibody-for-biliary-tract-cancer 2024-11-25T11:09:29+00:00 weekly 0.7 https://trial.medpath.com/news/an-open-label-phase-iii-study-to-assess-the-efficacy-and-safety-of-cy-opth 2024-11-25T10:56:39+00:00 weekly 0.7 https://trial.medpath.com/news/the-cost-effectiveness-of-peer-education-on-medication-adherence-in-the-elderly-with-hypertension 2024-11-25T10:56:01+00:00 weekly 0.7 https://trial.medpath.com/news/ticaros-unveils-breakthrough-switchable-car-t-therapy-for-solid-cancers-kbr 2024-11-25T10:49:28+00:00 weekly 0.7 https://trial.medpath.com/news/intravenous-administration-of-blood-brain-barrier-crossing-conjugates-facilitate-nature 2024-11-25T10:47:31+00:00 weekly 0.7 https://trial.medpath.com/news/homegrown-preoperative-lung-cancer-drug-leclaza-lowers-cancer-stages-in-55-of-patients 2024-11-25T10:44:15+00:00 weekly 0.7 https://trial.medpath.com/news/gcar-and-astrazeneca-execute-agreement-to-evaluate-azd1390-for-glioblastoma 2024-11-25T10:37:15+00:00 weekly 0.7 https://trial.medpath.com/news/europe-is-losing-competitiveness-in-the-medical-field-regulatory-regime-to-blame 2024-11-25T10:33:30+00:00 weekly 0.7 https://trial.medpath.com/news/alzheimer-disease-awareness-month-2024-looking-back-at-a-year-of-progress-in-cell-and 2024-11-25T10:27:05+00:00 weekly 0.7 https://trial.medpath.com/news/gcar-and-astrazeneca-execute-agreement-to-evaluate-azd1390-for-glioblastoma 2024-11-25T10:21:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-bridgebio-s-attruby-for-attr-cm-treatment-pharmaceutical-technology 2024-11-25T10:04:21+00:00 weekly 0.7 https://trial.medpath.com/news/pharmacodynamics-of-the-s1p1-receptor-modulator-cenerimod-in-a-phase-2b-randomised 2024-11-25T09:47:18+00:00 weekly 0.7 https://trial.medpath.com/news/using-an-electronic-tool-to-screen-patients-eligibility-for-clinical-trials-nursing-times 2024-11-25T09:42:18+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-bridgebio-s-attruby-for-attr-cm-treatment-yahoo 2024-11-25T09:41:49+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-s-blenrep-combinations-accepted-for-review-by-us-fda-morningstar 2024-11-25T09:09:55+00:00 weekly 0.7 https://trial.medpath.com/news/care-bundles-to-improve-enteral-nutrition-management-in-stroke-patients-trials-biomed-central 2024-11-25T09:05:46+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-fda-accepts-blenrep-combination-for-review-in-treatment-of-relapsed-refractory 2024-11-25T09:04:15+00:00 weekly 0.7 https://trial.medpath.com/news/injecting-oxygen-microbubbles-boston-children-s-answers 2024-11-25T09:03:27+00:00 weekly 0.7 https://trial.medpath.com/news/roche-receives-fda-approval-for-first-companion-diagnostic-to-identify-patients-with-biliary 2024-11-25T09:00:41+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-highlights-new-96-week-results-from-phase-iii-scemblix-r-asc4first-trial-at-ash 2024-11-25T09:00:41+00:00 weekly 0.7 https://trial.medpath.com/news/bridgebio-poised-to-challenge-pfizer-after-attruby-approval-pharmaphorum 2024-11-25T08:43:01+00:00 weekly 0.7 https://trial.medpath.com/news/efficacy-and-safety-of-the-combination-of-decitabine-and-chag-priming-regimen-in-the-nature 2024-11-25T08:34:31+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-prostate-cancer-drug-shows-promising-phase-iii-results-lse-azn 2024-11-25T08:06:30+00:00 weekly 0.7 https://trial.medpath.com/news/roche-gets-fda-approval-for-first-companion-diagnostic-for-her2-treatment-in-biliary 2024-11-25T08:05:19+00:00 weekly 0.7 https://trial.medpath.com/news/hanmi-pharmaceutical-and-beijing-hanmi-progress-clinical-trials-of-co-developed-bh3120 2024-11-25T07:56:25+00:00 weekly 0.7 https://trial.medpath.com/news/intracoronary-administration-of-tenecteplase-to-prevent-pci-related-myocardial-infarction-in-trials 2024-11-25T07:34:57+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-highlights-new-96-week-results-from-phase-iii-scemblix-r-asc4first-trial-at-ash 2024-11-25T07:30:57+00:00 weekly 0.7 https://trial.medpath.com/news/usfda-accepts-blenrep-combinations-for-treatment-of-relapsed-refractory-multiple-myeloma 2024-11-25T07:18:31+00:00 weekly 0.7 https://trial.medpath.com/news/blenrep-combinations-accepted-for-review-by-the-us-fda-for-the-treatment-of-relapsed-gsk 2024-11-25T07:07:20+00:00 weekly 0.7 https://trial.medpath.com/news/truqap-combination-in-pten-deficient-metastatic-hormone-sensitive-prostate-cancer-astrazeneca 2024-11-25T07:06:39+00:00 weekly 0.7 https://trial.medpath.com/news/vir-biotechnology-ceo-to-present-at-major-healthcare-conferences-in-early-2024 2024-11-25T07:01:32+00:00 weekly 0.7 https://trial.medpath.com/news/mydriasis-clinical-trials-2024-ema-pdma-fda-approvals-openpr-com 2024-11-25T06:45:23+00:00 weekly 0.7 https://trial.medpath.com/news/nasal-polyposis-clinical-trials-2024-ema-pdma-fda-approvals-openpr-com 2024-11-25T06:45:23+00:00 weekly 0.7 https://trial.medpath.com/news/rising-lung-cancer-rates-among-young-adults-prompt-shift-to-precision-oncology-approaches 2024-11-25T06:43:14+00:00 weekly 0.7 https://trial.medpath.com/news/roche-receives-fda-approval-for-first-companion-diagnostic-to-identify-patients-with-biliary 2024-11-25T06:34:19+00:00 weekly 0.7 https://trial.medpath.com/news/combination-of-eflornithine-and-lomustine-demonstrates-clinically-meaningful-biospace 2024-11-25T06:20:43+00:00 weekly 0.7 https://trial.medpath.com/news/global-coalition-for-adaptive-research-announces-evaluation-of-azd1390-in-gbm-agile-trial 2024-11-25T06:20:43+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-highlights-new-96-week-results-from-phase-iii-scemblix-r-asc4first-trial-at-ash 2024-11-25T06:18:46+00:00 weekly 0.7 https://trial.medpath.com/news/roche-secures-fda-approval-for-first-ever-her2-test-in-biliary-tract-cancer-stock-titan 2024-11-25T06:16:50+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-highlights-new-96-week-results-from-phase-iii-globenewswire 2024-11-25T06:16:18+00:00 weekly 0.7 https://trial.medpath.com/news/roche-receives-fda-approval-for-first-companion-diagnostic-to-identify-patients-with-biliary 2024-11-25T06:10:39+00:00 weekly 0.7 https://trial.medpath.com/news/roche-receives-fda-approval-for-first-companion-diagnostic-to-identify-patients-with-biliary 2024-11-25T06:03:54+00:00 weekly 0.7 https://trial.medpath.com/news/answer-als-cedars-sinai-collaboration-single-cell-protein-profiling-chapsvision 2024-11-25T06:02:45+00:00 weekly 0.7 https://trial.medpath.com/news/attrubytm-acoramidis-a-near-complete-ttr-stabilizer-90-approved-by-fda-to-biospace 2024-11-25T06:00:41+00:00 weekly 0.7 https://trial.medpath.com/news/alkannin-induces-g2-m-phase-arrest-apoptosis-and-inhibition-of-invas-dddt 2024-11-25T05:46:39+00:00 weekly 0.7 https://trial.medpath.com/news/johnson-johnson-seeks-us-fda-approval-for-subcutaneous-induction-regimen-of-tremfya 2024-11-25T05:31:42+00:00 weekly 0.7 https://trial.medpath.com/news/acne-vaccine-clinical-trials-to-be-held-here-by-a-star-national-skin-centre-and-sanofi 2024-11-25T05:26:51+00:00 weekly 0.7 https://trial.medpath.com/news/mursla-bio-announces-promising-results-for-evoliver-test-in-liver-cancer-detection 2024-11-25T05:20:09+00:00 weekly 0.7 https://trial.medpath.com/news/cassava-sciences-to-hold-corporate-update-on-november-25th-gurufocus 2024-11-25T05:09:01+00:00 weekly 0.7 https://trial.medpath.com/news/fda-action-alert-applied-therapeutics-awaits-verdict-on-rare-disease-therapy-biospace 2024-11-25T05:08:20+00:00 weekly 0.7 https://trial.medpath.com/news/embattled-sage-dealt-deeper-blow-with-huntington-s-failure-biospace 2024-11-25T05:08:18+00:00 weekly 0.7 https://trial.medpath.com/news/bridgebio-s-breakthrough-in-rare-heart-condition-treatment-health-devdiscourse 2024-11-25T05:02:58+00:00 weekly 0.7 https://trial.medpath.com/news/game-changing-solution-for-heart-inflammation-david-elsley-cardiol-therapeutics 2024-11-25T04:51:14+00:00 weekly 0.7 https://trial.medpath.com/news/novotech-publishes-comprehensive-report-on-the-global-vaccine-clinical-trials-landscape 2024-11-25T04:49:18+00:00 weekly 0.7 https://trial.medpath.com/news/iicon-supports-new-phase-ii-trial-of-novel-pneumococcal-vaccine-pnubiovax-pharmabiz 2024-11-25T04:32:13+00:00 weekly 0.7 https://trial.medpath.com/news/quick-listen-scrip-s-five-must-know-things-citeline-news-insights 2024-11-25T04:08:35+00:00 weekly 0.7 https://trial.medpath.com/news/hanmi-pharmaceutical-and-beijing-hanmi-progress-clinical-trials-of-co-developed-bh3120 2024-11-25T03:01:48+00:00 weekly 0.7 https://trial.medpath.com/news/fda-links-asthma-drug-singulair-to-mental-health-side-effects-suicides-times-now 2024-11-25T02:41:53+00:00 weekly 0.7 https://trial.medpath.com/news/european-drug-shortages-hit-record-levels-norway-and-generics-most-affected 2024-11-25T02:07:06+00:00 weekly 0.7 https://trial.medpath.com/news/break-it-down-neurotech-s-human-adult-study-tick-of-approval-for-cannabinoid-drug 2024-11-25T02:00:29+00:00 weekly 0.7 https://trial.medpath.com/news/hanmi-pharmaceutical-and-beijing-hanmi-progress-clinical-trials-of-co-developed-bh3120 2024-11-25T01:32:39+00:00 weekly 0.7 https://trial.medpath.com/news/how-stimulating-a-nerve-could-stop-uncontrolled-bleeding-in-postpartum-women-kmvt 2024-11-25T01:28:09+00:00 weekly 0.7 https://trial.medpath.com/news/effective-sponsor-oversight-critical-for-cro-partnerships-in-clinical-trials-industry-leaders-emphasize 2024-11-25T01:27:53+00:00 weekly 0.7 https://trial.medpath.com/news/cassava-sciences-to-hold-corporate-update-on-november-25th-quantisnow 2024-11-25T01:17:01+00:00 weekly 0.7 https://trial.medpath.com/news/neurotech-international-advances-nti164-drug-trials-markets-insider 2024-11-25T01:13:58+00:00 weekly 0.7 https://trial.medpath.com/news/cassava-sciences-to-hold-corporate-update-on-november-25th-globenewswire 2024-11-25T01:03:48+00:00 weekly 0.7 https://trial.medpath.com/news/innovent-to-present-clinical-data-of-multiple-novel-molecules-at-esmo-asia-2024-pr-newswire 2024-11-25T01:00:51+00:00 weekly 0.7 https://trial.medpath.com/news/jacobio-pharmaceuticals-advances-with-new-cancer-drug-trial-tipranks-com 2024-11-25T00:46:40+00:00 weekly 0.7 https://trial.medpath.com/news/spatial-interactions-of-immune-cells-as-potential-predictors-to-efficacy-of-toripalimab-plus 2024-11-25T00:42:29+00:00 weekly 0.7 https://trial.medpath.com/news/innovent-to-present-clinical-data-of-multiple-novel-molecules-at-esmo-asia-2024 2024-11-25T00:41:26+00:00 weekly 0.7 https://trial.medpath.com/news/jefferies-reaffirms-buy-rating-on-argenx-stock-ups-target-amid-promising-trial-updates 2024-11-25T00:24:09+00:00 weekly 0.7 https://trial.medpath.com/news/ssy-group-gains-approval-for-key-drug-development-tipranks-com 2024-11-25T00:08:42+00:00 weekly 0.7 https://trial.medpath.com/news/unveiling-the-progress-and-challenges-in-the-fight-against-hiv-technology-networks 2024-11-25T00:07:09+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-rystiggo-r-rozanolixizumab-noli-for-generalized-myasthenia-gravis-treatment 2024-11-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-safety-analysis-reveals-new-adverse-events-for-plecanatide-beyond-clinical-trial-data 2024-11-25T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/alpheus-medical-announces-positive-phase-1-2-trial-results-for-the-treatment-of-recurrent-high-grade-gliomas 2024-11-24T23:11:20+00:00 weekly 0.7 https://trial.medpath.com/news/miracle-drug-sees-blood-cancer-patients-given-second-chance-of-life-uk-daily-express 2024-11-24T22:56:38+00:00 weekly 0.7 https://trial.medpath.com/news/neurotech-international-advances-nti164-drug-trials-tipranks-com 2024-11-24T21:35:48+00:00 weekly 0.7 https://trial.medpath.com/news/comparison-of-two-doses-of-vitamin-d3-in-critically-ill-patients-undergoing-continuous-renal 2024-11-24T20:33:25+00:00 weekly 0.7 https://trial.medpath.com/news/these-2-key-milestones-awaiting-recce-pharmaceuticals-could-be-very-exciting-and-value-accretive 2024-11-24T20:04:08+00:00 weekly 0.7 https://trial.medpath.com/news/idh-inhibitor-activity-in-brain-cancer-persists-with-longer-follow-up-medpage-today 2024-11-24T20:00:58+00:00 weekly 0.7 https://trial.medpath.com/news/servier-s-vorasidenib-receives-approval-as-clinical-urgently-needed-drug-to-be-used-in 2024-11-24T19:34:23+00:00 weekly 0.7 https://trial.medpath.com/news/european-medicines-agency-ema-grants-orphan-medicinal-product-designation-for-ocu410st 2024-11-24T19:23:04+00:00 weekly 0.7 https://trial.medpath.com/news/accelerated-approval-sought-for-rp1-nivolumab-combo-for-pretreated-melanoma 2024-11-24T19:11:42+00:00 weekly 0.7 https://trial.medpath.com/news/fda-highlights-and-health-concerns-from-heart-drugs-to-mpox-updates-devdiscourse 2024-11-24T18:58:52+00:00 weekly 0.7 https://trial.medpath.com/news/servier-s-vorasidenib-receives-approval-as-clinical-urgently-needed-drug-to-be-used-in 2024-11-24T18:58:43+00:00 weekly 0.7 https://trial.medpath.com/news/enveda-130-million-series-c-raised-to-translate-nature-into-new-medicines 2024-11-24T18:48:26+00:00 weekly 0.7 https://trial.medpath.com/news/servier-s-vorasidenib-receives-approval-as-clinical-urgently-needed-drug-to-be-used-in 2024-11-24T18:28:43+00:00 weekly 0.7 https://trial.medpath.com/news/membrane-becomes-latest-rct-to-demonstrate-mma-embolisation-s-benefits-in-csdh-treatment 2024-11-24T18:23:28+00:00 weekly 0.7 https://trial.medpath.com/news/servier-s-vorasidenib-receives-approval-as-clinical-urgently-needed-drug-to-be-used-in 2024-11-24T18:22:39+00:00 weekly 0.7 https://trial.medpath.com/news/larotrectinib-induces-rapid-durable-responses-in-pediatric-patients-with-trk-fusion 2024-11-24T18:08:10+00:00 weekly 0.7 https://trial.medpath.com/news/down-47-since-march-is-crispr-therapeutics-stock-a-buy-on-the-dip 2024-11-24T17:54:00+00:00 weekly 0.7 https://trial.medpath.com/news/conduct-phase-iii-ct-cdsco-panel-tells-zydus-healthcare-on-glycopyrrolatem-plus 2024-11-24T17:20:19+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-results-of-durvalumab-tremelimumab-in-u-hcc-show-promise-despite-line-of-therapy 2024-11-24T16:50:11+00:00 weekly 0.7 https://trial.medpath.com/news/researchers-id-key-mechanism-behind-drug-resistant-prostate-cancer-fingerlakes1-com 2024-11-24T15:59:39+00:00 weekly 0.7 https://trial.medpath.com/news/zymeworks-gains-buy-rating-amid-fda-approval-and-market-expansion-potential-for-zanidatamab 2024-11-24T15:39:15+00:00 weekly 0.7 https://trial.medpath.com/news/founded-in-1954-korea-has-chosen-open-innovation-to-develop-products-in-cooperation 2024-11-24T15:31:22+00:00 weekly 0.7 https://trial.medpath.com/news/novel-p53-mdm2-inhibitor-plus-ribociclib-demonstrates-anticancer-activity-in-liposarcoma-subset 2024-11-24T15:07:49+00:00 weekly 0.7 https://trial.medpath.com/news/how-functional-and-genomic-precision-medicine-are-getting-closer-to-matching-each 2024-11-24T15:07:39+00:00 weekly 0.7 https://trial.medpath.com/news/down-47-since-march-is-crispr-therapeutics-stock-a-buy-on-the-dip 2024-11-24T15:06:04+00:00 weekly 0.7 https://trial.medpath.com/news/luna-optic-data-support-long-term-benefit-of-ixo-vec-for-wet-amd-hcplive 2024-11-24T14:16:47+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-in-nmda-receptors-research-could-reshape-depression-treatments-study-suggests 2024-11-24T14:13:37+00:00 weekly 0.7 https://trial.medpath.com/news/dr-hansford-on-hrqol-outcomes-with-tovorafenib-in-pediatric-braf-altered-low-grade-glioma 2024-11-24T14:10:20+00:00 weekly 0.7 https://trial.medpath.com/news/dr-gershon-on-deep-responses-with-mirdametinib-in-nf1-pn-onclive 2024-11-24T13:56:26+00:00 weekly 0.7 https://trial.medpath.com/news/trastuzumab-duocarmazine-in-previously-treated-her2-positive-metastatic-breast-cancer 2024-11-24T13:45:31+00:00 weekly 0.7 https://trial.medpath.com/news/the-targeted-pulse-discover-key-fda-actions-in-leukemia-and-nsclc-and-the 2024-11-24T12:03:26+00:00 weekly 0.7 https://trial.medpath.com/news/cellcentric-business-weekly 2024-11-24T11:30:22+00:00 weekly 0.7 https://trial.medpath.com/news/bios-health-business-weekly 2024-11-24T11:30:22+00:00 weekly 0.7 https://trial.medpath.com/news/cerevance-business-weekly 2024-11-24T11:30:22+00:00 weekly 0.7 https://trial.medpath.com/news/down-47-since-march-is-crispr-therapeutics-stock-a-buy-on-the-dip-yahoo-finance 2024-11-24T11:28:12+00:00 weekly 0.7 https://trial.medpath.com/news/anavex-striving-for-excellence-in-rett-syndrome-trial-rttnews 2024-11-24T10:37:06+00:00 weekly 0.7 https://trial.medpath.com/news/how-valve-type-anesthesia-strategy-affect-tavr-outcomes-cardiologists-perform-live 2024-11-24T10:07:13+00:00 weekly 0.7 https://trial.medpath.com/news/bridgebio-pharma-fda-approves-heart-disease-drug-acoramidis-rttnews 2024-11-24T09:40:11+00:00 weekly 0.7 https://trial.medpath.com/news/replimune-receives-breakthrough-therapy-designation-for-rp1-and-submits-pipelinereview 2024-11-24T09:15:14+00:00 weekly 0.7 https://trial.medpath.com/news/tetris-used-as-therapy-to-reduce-ptsd-symptoms-in-pandemic-healthcare-workers 2024-11-24T09:08:56+00:00 weekly 0.7 https://trial.medpath.com/news/meta-analysis-supports-potential-use-of-ketamine-for-ptsd-ocd-hcplive 2024-11-24T09:01:09+00:00 weekly 0.7 https://trial.medpath.com/news/revolutionary-drug-approvals-and-global-health-updates-devdiscourse 2024-11-24T08:59:17+00:00 weekly 0.7 https://trial.medpath.com/news/consent-related-outcomes-in-the-alteplase-compared-to-tenecteplase-trial-pubmed 2024-11-24T07:00:52+00:00 weekly 0.7 https://trial.medpath.com/news/patient-dies-in-neurogene-s-phase-i-ii-rett-syndrome-trial-msn 2024-11-24T06:52:35+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-treatment-cures-rare-deadly-skin-disease-for-1st-time-newsbytes 2024-11-24T06:33:29+00:00 weekly 0.7 https://trial.medpath.com/news/ai-model-predicts-risk-of-post-operative-afib-cerebral-protection-devices-tavr 2024-11-24T06:03:51+00:00 weekly 0.7 https://trial.medpath.com/news/researchers-call-for-inclusive-cancer-trials-and-treatments-to-address-an-overlooked-source 2024-11-24T05:53:03+00:00 weekly 0.7 https://trial.medpath.com/news/humacyte-inc-shareholder-alert-robbins-llp-reminds-globenewswire 2024-11-24T05:26:59+00:00 weekly 0.7 https://trial.medpath.com/news/fda-s-ai-medical-device-regulation-gap-raises-safety-concerns-as-healthcare-ai-adoption-accelerates 2024-11-24T04:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/probiotics-shown-to-mitigate-effects-of-toxic-fire-retardant-chemicals-news-medical 2024-11-24T03:20:57+00:00 weekly 0.7 https://trial.medpath.com/news/diet-quality-body-weight-and-postmenopausal-hot-flashes-a-secondary-analysis-of-a 2024-11-24T03:18:34+00:00 weekly 0.7 https://trial.medpath.com/news/novotech-publishes-comprehensive-report-on-the-global-vaccine-clinical-trials-landscape 2024-11-24T02:13:31+00:00 weekly 0.7 https://trial.medpath.com/news/new-initiative-aims-to-explore-diet-s-role-in-lupus-care-news-medical 2024-11-24T01:28:53+00:00 weekly 0.7 https://trial.medpath.com/news/breaking-health-news-fda-approves-drug-for-rare-heart-condition-and-more 2024-11-24T00:59:57+00:00 weekly 0.7 https://trial.medpath.com/news/lipella-pharma-completes-dosing-for-first-cohort-in-phase-2a-trial-of-lp-310-for-oral-lichen-planus 2024-11-24T00:30:41+00:00 weekly 0.7 https://trial.medpath.com/news/novotech-publishes-comprehensive-report-on-the-global-vaccine-clinical-trials-landscape 2024-11-24T00:25:44+00:00 weekly 0.7 https://trial.medpath.com/news/tango-therapeutics-reports-third-quarter-2024-financial-results-gurufocus 2024-11-24T00:14:58+00:00 weekly 0.7 https://trial.medpath.com/news/updated-zanidatamab-data-shows-durable-response-in-biliary-tract-cancer 2024-11-24T00:03:36+00:00 weekly 0.7 https://trial.medpath.com/news/u-s-fda-found-asthma-drug-singular-montelukast-impacts-the-brain-reuters-says 2024-11-23T23:35:27+00:00 weekly 0.7 https://trial.medpath.com/news/this-week-in-ophthalmology-week-of-november-18-2024 2024-11-23T23:04:15+00:00 weekly 0.7 https://trial.medpath.com/news/dr-harding-on-the-fda-approval-of-zanidatamab-for-her2-biliary-tract-cancer-onclive 2024-11-23T22:53:22+00:00 weekly 0.7 https://trial.medpath.com/news/drug-company-deal-delivers-hope-for-dementia-business-scoop 2024-11-23T22:07:47+00:00 weekly 0.7 https://trial.medpath.com/news/drug-company-deal-delivers-hope-for-dementia-auckland-scoop 2024-11-23T22:07:45+00:00 weekly 0.7 https://trial.medpath.com/news/behind-the-phase-1-study-of-tar-210-in-fgfr-altered-nmibc-targeted-oncology 2024-11-23T22:03:27+00:00 weekly 0.7 https://trial.medpath.com/news/3-reasons-why-buying-madrigal-pharmaceuticals-today-is-a-wise-move-yahoo-finance 2024-11-23T20:25:54+00:00 weekly 0.7 https://trial.medpath.com/news/vorasidenib-shows-consistent-efficacy-with-manageable-safety-in-idh1-2-mutant-diffuse-glioma 2024-11-23T19:47:58+00:00 weekly 0.7 https://trial.medpath.com/news/a-journey-into-the-unknown-with-my-daughter-s-aggressive-brain-cancer-cure-today 2024-11-23T19:44:56+00:00 weekly 0.7 https://trial.medpath.com/news/first-patient-dosed-in-phase-i-iia-clinical-trial-of-abi-110-modern-retina 2024-11-23T19:25:09+00:00 weekly 0.7 https://trial.medpath.com/news/health-equity-access-weekly-roundup-november-23-2024 2024-11-23T19:03:20+00:00 weekly 0.7 https://trial.medpath.com/news/chinese-scientists-report-promising-results-from-novel-alzheimer-s-surgery-here-s-how 2024-11-23T18:53:55+00:00 weekly 0.7 https://trial.medpath.com/news/govt-launches-india-s-first-indigenous-antibiotic-nafithromycin-indiamedtoday 2024-11-23T18:24:47+00:00 weekly 0.7 https://trial.medpath.com/news/viltolarsen-slows-dmd-progression-in-small-study 2024-11-23T18:09:37+00:00 weekly 0.7 https://trial.medpath.com/news/tovorafenib-leads-to-durable-off-treatment-responses-in-pediatric-braf-altered-r-r-low 2024-11-23T18:07:35+00:00 weekly 0.7 https://trial.medpath.com/news/consider-brca-hrd-status-before-deciding-on-a-parp-inhibitor-for-ovarian-cancer 2024-11-23T18:02:10+00:00 weekly 0.7 https://trial.medpath.com/news/nano2-plus-radiation-temozolomide-is-under-exploration-in-newly-diagnosed-glioblastoma 2024-11-23T17:55:24+00:00 weekly 0.7 https://trial.medpath.com/news/novotech-publishes-comprehensive-report-on-the-global-vaccine-clinical-trials-landscape 2024-11-23T17:53:34+00:00 weekly 0.7 https://trial.medpath.com/news/surprising-link-between-covid-and-cancer-a-potential-breakthrough-health 2024-11-23T17:01:26+00:00 weekly 0.7 https://trial.medpath.com/news/belantamab-mafodotin-achieves-secondary-end-point-for-treatment-of-relapsed-refractory 2024-11-23T16:53:52+00:00 weekly 0.7 https://trial.medpath.com/news/j-j-submits-sbla-for-guselkumab-tremfya-subcutaneous-induction-regimen-in-uc 2024-11-23T16:32:24+00:00 weekly 0.7 https://trial.medpath.com/news/what-happened-in-optometry-this-week-november-18-november-22 2024-11-23T16:32:22+00:00 weekly 0.7 https://trial.medpath.com/news/zenyaku-kogyo-receives-japanese-approval-for-anti-cd20-monoclonal-antibody-rituxan-to 2024-11-23T16:30:29+00:00 weekly 0.7 https://trial.medpath.com/news/social-determinants-drive-disparities-in-pediatric-stem-cell-transplant-outcomes-and-access 2024-11-23T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/acuitive-technologies-receives-fda-510-k-clearance-of-bioactive-bone-void-filler-healio 2024-11-23T15:44:38+00:00 weekly 0.7 https://trial.medpath.com/news/all-news-alzforum 2024-11-23T15:40:11+00:00 weekly 0.7 https://trial.medpath.com/news/japan-s-mhlw-grants-expanded-indication-approval-to-gsk-s-rsv-vaccine-arexvy-for-pharmabiz 2024-11-23T15:30:56+00:00 weekly 0.7 https://trial.medpath.com/news/over-100-mn-doses-of-russia-s-sputnik-v-covid-19-vaccine-to-be-produced-in-india 2024-11-23T14:45:24+00:00 weekly 0.7 https://trial.medpath.com/news/the-role-of-the-estimand-framework-in-the-analysis-of-patient-reported-outcomes-in-single-arm-trials 2024-11-23T14:30:05+00:00 weekly 0.7 https://trial.medpath.com/news/first-fda-approved-retinal-gene-therapy-available-at-mayo-clinic 2024-11-23T14:24:13+00:00 weekly 0.7 https://trial.medpath.com/news/dr-janjigian-on-the-fda-approval-of-zolbetuximab-for-cldn18-2-gastric-gej-adenocarcinoma 2024-11-23T13:57:21+00:00 weekly 0.7 https://trial.medpath.com/news/novel-relapsed-refractory-cll-therapies-have-similar-safety-profiles 2024-11-23T13:30:44+00:00 weekly 0.7 https://trial.medpath.com/news/rlf-td011-spray-fights-bacteria-aids-wound-healing-phase-1-trial 2024-11-23T13:02:54+00:00 weekly 0.7 https://trial.medpath.com/news/leads-biolabs-receives-us-fda-orphan-drug-designation-for-anti-pd-l1-4-1bb-bispecific 2024-11-23T12:32:10+00:00 weekly 0.7 https://trial.medpath.com/news/dr-lukas-on-survival-outcomes-with-eflornithine-in-idh-mutant-anaplastic-astrocytoma 2024-11-23T12:14:50+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-nerivio-for-migraine-treatment-in-children-aged-8-years-and-older 2024-11-23T12:05:19+00:00 weekly 0.7 https://trial.medpath.com/news/trexbio-84-million-series-b-closed-to-decode-human-tissue-immune-biology 2024-11-23T12:02:48+00:00 weekly 0.7 https://trial.medpath.com/news/metsera-215-million-series-b-raised-to-develop-medicines-for-obesity-and-metabolic-diseases 2024-11-23T12:02:47+00:00 weekly 0.7 https://trial.medpath.com/news/parkinson-agent-solengepras-enters-phase-3-sage-to-discontinue-sage-718-serious 2024-11-23T12:02:13+00:00 weekly 0.7 https://trial.medpath.com/news/chmp-issues-positive-opinion-for-the-marketing-authorization-of-fyb203-a-biosimilar 2024-11-23T12:00:21+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-announces-japan-s-mhlw-approved-application-to-extend-indication-of-arexvy 2024-11-23T11:46:18+00:00 weekly 0.7 https://trial.medpath.com/news/zevra-therapeutics-launches-miplyffa-for-niemann-pick-disease-yahoo-finance 2024-11-23T11:39:40+00:00 weekly 0.7 https://trial.medpath.com/news/the-oncfive-top-oncology-articles-for-the-week-of-11-17-onclive 2024-11-23T11:34:53+00:00 weekly 0.7 https://trial.medpath.com/news/two-firms-aim-to-create-functional-cure-for-type-1-diabetes-the-streetwise-reports 2024-11-23T11:26:13+00:00 weekly 0.7 https://trial.medpath.com/news/midlothian-gp-practice-champions-clinical-research-healthandcare-scot 2024-11-23T11:20:28+00:00 weekly 0.7 https://trial.medpath.com/news/replimune-stock-rallies-on-bla-filing-for-melanoma-combo-drug-yahoo-finance 2024-11-23T10:24:30+00:00 weekly 0.7 https://trial.medpath.com/news/psma-targeted-radiation-drug-for-prostate-cancer-subset-meets-study-goal-cure-today 2024-11-23T10:18:13+00:00 weekly 0.7 https://trial.medpath.com/news/fda-accepts-resubmitted-nda-for-ataluren-in-nonsense-duchenne-muscular-dystrophy 2024-11-23T09:36:49+00:00 weekly 0.7 https://trial.medpath.com/news/trials-needed-for-sequencing-checkpoint-inhibitors-in-bladder-cancer-targeted-oncology 2024-11-23T09:13:29+00:00 weekly 0.7 https://trial.medpath.com/news/ivig-shows-promise-in-neuroimmune-disorders-with-potential-applications-for-long-covid-treatment 2024-11-23T09:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/novel-treatment-strategies-emerge-for-neuroendocrine-tumors-from-surveillance-to-captem-therapy 2024-11-23T09:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bridgebio-heart-drug-approved-by-fda-setting-up-battle-with-pfizer-yahoo-finance 2024-11-23T08:49:39+00:00 weekly 0.7 https://trial.medpath.com/news/cgtlive-r-s-weekly-rewind-november-22-2024 2024-11-23T08:15:21+00:00 weekly 0.7 https://trial.medpath.com/news/violette-trial-shows-precise-planning-in-prostate-cancer-microwave-ablation 2024-11-23T07:14:37+00:00 weekly 0.7 https://trial.medpath.com/news/mri-scans-at-triple-the-speed-and-just-as-sharp-alzforum 2024-11-23T07:10:15+00:00 weekly 0.7 https://trial.medpath.com/news/study-links-tooth-loss-to-increased-risk-of-sleep-apnea-highlighting-dental-sleep-health-connection 2024-11-23T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/intensity-therapeutics-is-establishing-a-new-field-of-localized-cancer-reduction-ceo 2024-11-23T06:56:16+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-iloperidone-fanapt-r-for-bipolar-i-disorder-open-minds 2024-11-23T06:07:02+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-medications-show-promise-in-reducing-lipoprotein-a-levels-by-up-to-90 2024-11-23T06:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bridgebio-announces-fda-approved-attruby-for-attr-cm-patients-markets-insider 2024-11-23T05:17:06+00:00 weekly 0.7 https://trial.medpath.com/news/a-glimpse-of-noncoding-rnas-secondary-structure-emerging-trends-and-potential 2024-11-23T04:53:31+00:00 weekly 0.7 https://trial.medpath.com/news/purdue-university-and-akston-biosciences-bring-first-dose-of-hope-in-new-cancer 2024-11-23T04:52:41+00:00 weekly 0.7 https://trial.medpath.com/news/advances-in-tnbc-mixed-news-in-lung-cancer-report-pancreatic-cancer-overdiagnosis 2024-11-23T04:28:14+00:00 weekly 0.7 https://trial.medpath.com/news/real-world-study-confirms-similar-efficacy-of-guselkumab-and-il-17i-for-psa-hcplive 2024-11-23T04:27:56+00:00 weekly 0.7 https://trial.medpath.com/news/the-big-give-christmas-challenge-2024-cure-parkinson-s 2024-11-23T04:19:24+00:00 weekly 0.7 https://trial.medpath.com/news/nuanced-and-far-reaching-effects-of-gamma-secretase-inhibition-in-the-multiple-myeloma-patients 2024-11-23T03:37:34+00:00 weekly 0.7 https://trial.medpath.com/news/launch-of-the-lola-project-for-the-non-invasive-detection-of-lung-and-colon-cancer-ibs-granada 2024-11-23T03:34:34+00:00 weekly 0.7 https://trial.medpath.com/news/treatment-of-oligometastatic-egfr-mutant-lung-cancer-medpage-today 2024-11-23T03:31:39+00:00 weekly 0.7